<?xml version="1.0" encoding="ISO-8859-1"?><COCHRANE_REVIEW DESCRIPTION="For publication" DOI="10.1002/14651858.CD000099.pub3" GROUP_ID="MENSTR" ID="692599072614410628" MERGED_FROM="" MODIFIED="2010-09-21 01:22:54 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;Exported from Review Manager 4.3.1&lt;br&gt;Exported from Review Manager 4.2.2&lt;br&gt;Exported from Review Manager 4.2.1&lt;br&gt;Exported from Review Manager 4.2&lt;br&gt;Short title (no longer in use): IVF:Growth hormone&lt;/p&gt;&lt;p&gt;&lt;/p&gt;" NOTES_MODIFIED="2009-08-24 10:52:08 +1200" NOTES_MODIFIED_BY="jane clarke" REVIEW_NO="KH 291" REVMAN_SUB_VERSION="5.0.21" REVMAN_VERSION="5" SPLIT_FROM="" STAGE="R" STATUS="A" TYPE="INTERVENTION" VERSION_NO="7.0">
<COVER_SHEET MODIFIED="2010-09-21 01:22:54 +0200" MODIFIED_BY="Jane Clarke">
<TITLE>Growth hormone for in vitro fertilization</TITLE>
<CONTACT MODIFIED="2010-09-21 01:22:54 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="0256F45882E26AA200CD32E5F73F3F60" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>James</FIRST_NAME><MIDDLE_INITIALS>MN</MIDDLE_INITIALS><LAST_NAME>Duffy</LAST_NAME><POSITION>Foundation Year One Doctor (Academic Surgery)</POSITION><EMAIL_1>jamesmnduffy@hotmail.co.uk</EMAIL_1><ADDRESS><ORGANISATION>Guy's and St Thomas' Hospital</ORGANISATION><ADDRESS_1>Westiminster Bridge Road</ADDRESS_1><CITY>London</CITY><ZIP>SE1 7EH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 77980115547</PHONE_1></ADDRESS></PERSON></CONTACT>
<CREATORS MODIFIED="2010-09-21 01:22:54 +0200" MODIFIED_BY="Jane Clarke"><PERSON ID="0256F45882E26AA200CD32E5F73F3F60" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>James</FIRST_NAME><MIDDLE_INITIALS>MN</MIDDLE_INITIALS><LAST_NAME>Duffy</LAST_NAME><POSITION>Foundation Year One Doctor (Academic Surgery)</POSITION><EMAIL_1>jamesmnduffy@hotmail.co.uk</EMAIL_1><ADDRESS><ORGANISATION>Guy's and St Thomas' Hospital</ORGANISATION><ADDRESS_1>Westiminster Bridge Road</ADDRESS_1><CITY>London</CITY><ZIP>SE1 7EH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 77980115547</PHONE_1></ADDRESS></PERSON><PERSON ID="F9B3654982E26AA20025F63939E7A472" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Gaity</FIRST_NAME><LAST_NAME>Ahmad</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>gaityahmad@hotmail.com</EMAIL_1><EMAIL_2>gaityahmad@aol.com</EMAIL_2><ADDRESS><DEPARTMENT>Obstetrics &amp; Gynaecology</DEPARTMENT><ORGANISATION>Pennine Acute NHS Trust</ORGANISATION><CITY>Manchester</CITY><COUNTRY CODE="GB">UK</COUNTRY></ADDRESS></PERSON><PERSON ID="A35617CD82E26AA2005347C3C9C537F5" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Lamiya</FIRST_NAME><LAST_NAME>Mohiyiddeen</LAST_NAME><POSITION>Specialist Registrar</POSITION><EMAIL_1>lamisalu@yahoo.com</EMAIL_1><ADDRESS><DEPARTMENT>Obstetrics and Gynaecology</DEPARTMENT><ORGANISATION>Northwestern Deanery, Manchester</ORGANISATION><ADDRESS_1>9 Harwell road, West Timperley, Altringham</ADDRESS_1><CITY>Manchester</CITY><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+0044 7974965002</PHONE_1></ADDRESS></PERSON><PERSON ID="BB27167882E26AA201A0DF30191B165E" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Luciano</FIRST_NAME><MIDDLE_INITIALS>G</MIDDLE_INITIALS><LAST_NAME>Nardo</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>Luciano.Nardo@cmmc.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Reproductive Medicine</DEPARTMENT><ORGANISATION>St Mary's Hosiptal, CMMC University Hospitals NHS Trust</ORGANISATION><ADDRESS_1>Whitworth Park</ADDRESS_1><CITY>Manchester</CITY><ZIP>M13 0JH</ZIP><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 276 6534 ext 6802</PHONE_1><FAX_1>+44 161 224 0957</FAX_1></ADDRESS></PERSON><PERSON ID="0A9FF8B382E26AA200DE9984F9827998" ROLE="AUTHOR"><PREFIX>Dr</PREFIX><FIRST_NAME>Andrew</FIRST_NAME><LAST_NAME>Watson</LAST_NAME><POSITION>Consultant</POSITION><EMAIL_1>andy.watson@tgh.nhs.uk</EMAIL_1><ADDRESS><DEPARTMENT>Tameside &amp; Glossop Acute Services NHS Trust</DEPARTMENT><ORGANISATION>Tameside General Hospital</ORGANISATION><ADDRESS_1>Fountain Street</ADDRESS_1><CITY>Ashton-Under-Lyme</CITY><ZIP>OL6 9RW</ZIP><REGION>Lancashire</REGION><COUNTRY CODE="GB">UK</COUNTRY><PHONE_1>+44 161 3316158</PHONE_1><PHONE_2>+44 1332 75148</PHONE_2><FAX_1>+44 161 331 6074</FAX_1></ADDRESS></PERSON></CREATORS>
<DATES MODIFIED="2010-09-21 01:22:54 +0200" MODIFIED_BY="Jane Clarke" NOTES="&lt;p&gt;New studies found and included or excluded: 3/24/03&lt;/p&gt;&lt;p&gt;Conclusions changed: 5/28/03&lt;/p&gt;" NOTES_MODIFIED="2009-08-24 10:27:41 +1200" NOTES_MODIFIED_BY="Jane Clarke">
<UP_TO_DATE>
<DATE DAY="20" MONTH="7" YEAR="2009"/>
</UP_TO_DATE>
<LAST_SEARCH>
<DATE DAY="1" MONTH="6" YEAR="2009"/>
</LAST_SEARCH>
<NEXT_STAGE>
<DATE DAY="1" MONTH="10" YEAR="2011"/>
</NEXT_STAGE>
<PROTOCOL_PUBLISHED ISSUE="1" YEAR="1995"/>
<REVIEW_PUBLISHED ISSUE="1" YEAR="1995"/>
<LAST_CITATION_ISSUE ISSUE="1" YEAR="2010"/>
</DATES>
<WHATS_NEW MODIFIED="2010-09-21 01:22:54 +0200" MODIFIED_BY="Jane Clarke"><WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2010-09-21 01:22:54 +0200" MODIFIED_BY="Jane Clarke"><DATE DAY="20" MONTH="9" YEAR="2010"/><DESCRIPTION><P>Contact details updated.</P></DESCRIPTION></WHATS_NEW_ENTRY>

</WHATS_NEW>
<HISTORY MODIFIED="2010-09-21 01:22:54 +0200" MODIFIED_BY="Jane Clarke"><WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2010-09-21 01:22:54 +0200" MODIFIED_BY="Jane Clarke">
<DATE DAY="24" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>Authors changed</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_OLD_CONCLUSIONS" MODIFIED="2009-08-24 10:51:41 +1200" MODIFIED_BY="jane clarke">
<DATE DAY="11" MONTH="8" YEAR="2009"/>
<DESCRIPTION>
<P>New authors added </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="UPDATE" MODIFIED="2009-08-24 10:51:44 +1200" MODIFIED_BY="jane clarke">
<DATE DAY="14" MONTH="6" YEAR="2009"/>
<DESCRIPTION>
<P>Since the last published review (1995 &amp; 2003), the authorship of the review has changed.  New authors involved in updating the review in 2009 included G Ahmad, J Brown, JMN Duffy, L Nardo, I Salim and AJ Watson.  New randomised controlled trials were included in the review, resulting from repeating the search strategy In June 2009.  Subgroup analysis of poor responders was performed in the 2009 update, the first subgroup defined as poor responders as demonstrated by sub-optimal response following controlled ovarian stimulation and the second subgroup defined as poor ovarian performance as demonstrated by abnormal ovarian reserve tests. </P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="AMENDMENT" MODIFIED="2009-06-15 00:14:03 +1200" MODIFIED_BY="James M N Duffy">
<DATE DAY="28" MONTH="4" YEAR="2008"/>
<DESCRIPTION>
<P>Converted to new review format.</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
<WHATS_NEW_ENTRY EVENT="NEW_CITATION_NEW_CONCLUSIONS">
<DATE DAY="28" MONTH="5" YEAR="2003"/>
<DESCRIPTION>
<P>Substantive amendment</P>
</DESCRIPTION>
</WHATS_NEW_ENTRY>
</HISTORY>
<SOURCES_OF_SUPPORT MODIFIED="2009-06-15 10:06:46 +1200" MODIFIED_BY="James M N Duffy">
<INTERNAL_SOURCES>
<SOURCE>
<NAME>Dept of Obstetrics and Gynaecology, University of Auckland</NAME>
<COUNTRY CODE="NZ">New Zealand</COUNTRY>
<DESCRIPTION/>
</SOURCE>
</INTERNAL_SOURCES>
<EXTERNAL_SOURCES MODIFIED="2009-06-15 10:06:46 +1200" MODIFIED_BY="James M N Duffy">
<SOURCE MODIFIED="2009-06-15 10:06:46 +1200" MODIFIED_BY="James M N Duffy">
<NAME>Department of Health</NAME>
<COUNTRY CODE="GB">UK</COUNTRY>
<DESCRIPTION>
<P>$5,000 initiative fund.</P>
</DESCRIPTION>
</SOURCE>
</EXTERNAL_SOURCES>
</SOURCES_OF_SUPPORT>
<MESH_TERMS VERIFIED="NO"/>
<KEYWORDS/>
</COVER_SHEET>
<MAIN_TEXT MODIFIED="2009-08-11 14:22:35 +1200" MODIFIED_BY="Julie A Brown">
<SUMMARY MODIFIED="2009-08-11 14:20:59 +1200" MODIFIED_BY="Julie A Brown">
<TITLE MODIFIED="2009-07-31 05:24:37 +1200" MODIFIED_BY="James M N Duffy">Growth hormone in in-vitro fertilisation</TITLE>
<SUMMARY_BODY MODIFIED="2009-08-11 14:20:59 +1200" MODIFIED_BY="Julie A Brown">
<P>Before starting an in-vitro fertilisation cycle, some women need help to ovulate and the use of growth hormone therapy may help these women. This aims to reduce the use of gonadotropin therapy to stimulate ovulation, a hormone that can cause multiple pregnancy. The review of trials found no evidence that growth hormone helps improve birth rates in women who are undergoing ovulation induction prior to in-vitro fertilisation. However there is some evidence of increased pregnancy and birth rates in women who are considered 'poor responders' to in-vitro fertilisation. More research is needed.</P>
</SUMMARY_BODY>
</SUMMARY>
<ABSTRACT MODIFIED="2009-08-11 14:20:21 +1200" MODIFIED_BY="Julie A Brown">
<ABS_BACKGROUND MODIFIED="2009-08-11 12:55:59 +1200" MODIFIED_BY="Julie A Brown">
<P>In an effort to improve outcomes of in-vitro fertilisation cycles the use of growth hormone has been considered. Improving the outcomes of in-vitro fertilisation is especially important for subfertile women who are considered 'poor responders'.</P>
</ABS_BACKGROUND>
<ABS_OBJECTIVES MODIFIED="2009-08-11 09:53:05 +1200" MODIFIED_BY="jane clarke">
<P>To assess the effectiveness of adjuvant growth hormone in in-vitro fertilisation protocols. </P>
</ABS_OBJECTIVES>
<ABS_SEARCH_STRATEGY MODIFIED="2009-08-11 09:53:15 +1200" MODIFIED_BY="jane clarke">
<P>We searched the Cochrane Menstrual Disorders and Subfertility Groups trials register (June 2009), the Cochrane Central Register of Controlled Trials (Cochrane Library Issue 2, 2009), MEDLINE (1966 to June 2009), EMBASE (1988 to June 2009) and Biological Abstracts (1969 to June 2009).</P>
</ABS_SEARCH_STRATEGY>
<ABS_SELECTION_CRITERIA MODIFIED="2009-08-11 09:53:53 +1200" MODIFIED_BY="jane clarke">
<P>All randomised controlled trials were included if they addressed the research question and provided outcome data for intervention and control participants.</P>
</ABS_SELECTION_CRITERIA>
<ABS_DATA_COLLECTION MODIFIED="2009-08-11 09:53:40 +1200" MODIFIED_BY="jane clarke">
<P>Assessment of trial risk of bias and extraction of relevant data was performed independently by two reviewers.</P>
</ABS_DATA_COLLECTION>
<ABS_RESULTS MODIFIED="2009-08-11 14:20:21 +1200" MODIFIED_BY="Julie A Brown">
<P>Ten studies (440 subfertile couples) were included. Results of the meta-analysis demonstrated no difference in outcome measures and adverse events in the routine use of adjuvant growth hormone in in-vitro fertilisation protocols. However, meta-analysis demonstrated a statistically significant difference in both live birth rates and pregnancy rates favouring the use of adjuvant growth hormone in in-vitro fertilisation protocols in women who are considered poor responders without increasing adverse events, OR 5.39, 95% CI 1.89 to 15.35 and OR 3.28, 95% CI 1.74 to 6.20 respectively.</P>
</ABS_RESULTS>
<ABS_CONCLUSIONS MODIFIED="2009-08-11 12:57:46 +1200" MODIFIED_BY="Julie A Brown">
<P>Although the use of growth hormone in poor responders has been found to show a significant improvement in live birth rates, we were unable to identify which sub-group of poor responders would benefit the most from adjuvant growth hormone. The result needs to be interpreted with caution, the included trials were few in number and small sample size. Therefore, before recommending growth hormone adjuvant in in-vitro fertilisation further research is necessary to fully define its role.</P>
</ABS_CONCLUSIONS>
</ABSTRACT>
<BODY MODIFIED="2009-08-11 14:22:35 +1200" MODIFIED_BY="Julie A Brown">
<BACKGROUND MODIFIED="2009-08-11 12:58:14 +1200" MODIFIED_BY="Julie A Brown">
<CONDITION MODIFIED="2009-08-11 09:54:39 +1200" MODIFIED_BY="jane clarke">
<P>Subfertility, usually defined as absence of conception after one year of regular intercourse, is a common problem affecting as many as one in six couples (<LINK REF="REF-Cahill-2002" TYPE="REFERENCE">Cahill 2002</LINK>). Main causes include sperm dysfunction, ovulation disorder and fallopian tube damage (<LINK REF="REF-Cahill-2002" TYPE="REFERENCE">Cahill 2002</LINK>). One method of treating infertile couples is assisted conception via in-vitro fertilisation (IVF). IVF involves using hormones to modify ovarian function in order to increase follicular growth and thus develop more than one oocyte. Ovulation is then triggered with human chorionic gonadotropin and the oocytes are retrieved and fertilised with sperm in the laboratory setting. The oocytes are then fertilised outside the body (in vitro). The fertilised oocytes (embryos) are then transferred into the uterus after 36 hours after oocyte retrieval. IVF protocols are constantly under review in an attempt to decrease hormone (gonadotrophin) requirement, improve follicular recruitment, whilst primarily to increase live birth rates.</P>
</CONDITION>
<INTERVENTION MODIFIED="2009-08-11 09:54:48 +1200" MODIFIED_BY="jane clarke">
<P>Some protocols have considered the role of growth hormone in IVF (<LINK REF="STD-Landolfi-1994" TYPE="STUDY">Landolfi 1994</LINK>; <LINK REF="STD-Jacobs-1995" TYPE="STUDY">Jacobs 1995</LINK>). Growth hormone is a biological peptide hormone, synthesised, stored and secreted by somatotroph cells located in the anterior pituitary gland. Growth hormone can be synthetically produced using recombinant DNA technology and is licensed to be used in the human population. There is currently no consensus as to the route, dose or timing of growth hormone administration in IVF protocols.</P>
</INTERVENTION>
<THEORY MODIFIED="2009-08-11 09:54:57 +1200" MODIFIED_BY="jane clarke">
<P>The administration of growth hormone may potentate the effect of exogenous gonadotrophins (<LINK REF="REF-Homburg-1988" TYPE="REFERENCE">Homburg 1988</LINK>). Growth hormone is reported to modulate the action of follicular stimulating hormone on granulosa cells by up-regulating the local synthesis of insulin-like growth factor-I (IGF-1). This interest has been stimulated by animal studies which suggest that growth hormone may increase the intra-ovarian production of the IGF-1 (<LINK REF="REF-Hsu-1987" TYPE="REFERENCE">Hsu 1987</LINK>; <LINK REF="REF-Yoshimura-1996" TYPE="REFERENCE">Yoshimura 1996</LINK>). IGF-1 displays growth hormone dependence both in-vivo and in-vitro (<LINK REF="REF-Blumenfeld-1996" TYPE="REFERENCE">Blumenfeld 1996</LINK>). The interaction between growth hormone and IGF-1 is of significance since IGF-1 has been shown to play an important part in ovarian function in both animal and human models (<LINK REF="REF-Adashi-1985" TYPE="REFERENCE">Adashi 1985</LINK>; <LINK REF="REF-Erickson-1989" TYPE="REFERENCE">Erickson 1989</LINK>).The addition of IGF-1 to gonadotrophins in granulosa cell cultures increased gonadotrophin action on the ovary by several mechanisms including augmentation of aromatase activity, 17 beta-oestradiol and progesterone production and luteinising hormone receptor formation (<LINK REF="REF-Erickson-1989" TYPE="REFERENCE">Erickson 1989</LINK>;<LINK REF="REF-Mason-1990" TYPE="REFERENCE">Mason 1990</LINK>). IGF-1 has also been found to stimulate follicular development, oestrogen production and oocyte maturation (<LINK REF="REF-Yoshimura-1996" TYPE="REFERENCE">Yoshimura 1996</LINK>).</P>
</THEORY>
<IMPORTANCE MODIFIED="2009-08-11 12:58:14 +1200" MODIFIED_BY="Julie A Brown">
<P>Improving the outcomes of IVF by the use of growth hormone adjuvant therapy is important particularly in those women who are considered poor responders. The aim of this review is to establish the role of growth hormone in IVF.</P>
</IMPORTANCE>
</BACKGROUND>
<OBJECTIVES MODIFIED="2009-08-11 09:56:34 +1200" MODIFIED_BY="jane clarke">
<P>To assess the effectiveness of adjuvant growth hormone in IVF. </P>
</OBJECTIVES>
<METHODS MODIFIED="2009-08-11 13:05:03 +1200" MODIFIED_BY="Julie A Brown">
<SELECTION_CRITERIA MODIFIED="2009-08-11 13:05:03 +1200" MODIFIED_BY="Julie A Brown">
<CRIT_STUDIES MODIFIED="2009-08-11 12:58:23 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomised controlled trials were eligible for inclusion. </P>
</CRIT_STUDIES>
<CRIT_PARTICIPANTS MODIFIED="2009-08-11 12:58:46 +1200" MODIFIED_BY="Julie A Brown">
<P>Women who were part of a subfertile couple undergoing IVF.</P>
</CRIT_PARTICIPANTS>
<CRIT_INTERVENTIONS MODIFIED="2009-08-11 09:57:32 +1200" MODIFIED_BY="jane clarke">
<P>All studies comparing adjuvant growth hormone in IVF cycles with standard IVF cycles. </P>
</CRIT_INTERVENTIONS>
<CRIT_OUTCOMES MODIFIED="2009-08-11 13:05:03 +1200" MODIFIED_BY="Julie A Brown">
<CRIT_OUTCOMES_PRIMARY MODIFIED="2009-08-11 13:04:25 +1200" MODIFIED_BY="Julie A Brown">
<P>1. Live birth rate per woman randomised</P>
<P>Number of women achieving a live birth divided by the number of women randomised.</P>
</CRIT_OUTCOMES_PRIMARY>
<CRIT_OUTCOMES_SECONDARY MODIFIED="2009-08-11 13:05:03 +1200" MODIFIED_BY="Julie A Brown">
<P>1. Pregnancy rate per woman randomised.</P>
<P>Number of women achieving a clinical pregnancy (established with a human chorionic gonadotropin test in blood or urine and/or confirmed by ultrasound) divided by the number of women randomised. </P>
<P>2. Oocytes retrieved per woman randomised.</P>
<P>Number of women with at least one oocyte retrieved divided by the number of women randomised.<BR/>
</P>
<P>3. Embryo transfer per woman randomised.</P>
<P>Number of women with at least one embryo transferred divided by the number of women randomised.<BR/>
</P>
<P>4. Ampoules of gonadotrophin used.</P>
<P>The mean number of ampoules used per woman.<BR/>
</P>
<P>5. Adverse events (e.g. ovarian hyperstimulation syndrome).</P>
</CRIT_OUTCOMES_SECONDARY>
</CRIT_OUTCOMES>
</SELECTION_CRITERIA>
<SEARCH_METHODS MODIFIED="2009-08-11 09:58:28 +1200" MODIFIED_BY="jane clarke">
<ELECTRONIC_SEARCHES MODIFIED="2009-08-11 09:58:07 +1200" MODIFIED_BY="jane clarke">
<P>The following electronic databases, trial registers and web sites were searched up until June 2009: The Menstrual Disorders and Subfertility Group (MDSG) Specialised Register of Controlled Trials (<LINK REF="APP-01" TYPE="APPENDIX">Appendix 1</LINK>), MEDLINE (<LINK REF="APP-02" TYPE="APPENDIX">Appendix 2</LINK>), EMBASE (<LINK REF="APP-03" TYPE="APPENDIX">Appendix 3</LINK>), the Cochrane Central Register of Controlled Trials (<LINK REF="APP-04" TYPE="APPENDIX">Appendix 4</LINK>), and PSYCINFO (<LINK REF="APP-05" TYPE="APPENDIX">Appendix 5</LINK>).</P>
<P>The MEDLINE search was combined with the Cochrane highly sensitive search strategy for identifying randomised trials, which appears in the searching chapter of The Cochrane Handbook of Systematic Reviews of Interventions. The EMBASE search was combined with trial filters developed by the Scottish Intercollegiate Guidelines Network (SIGN) (http://www.sign.ac.uk/methodology/filters.html#random)<BR/>
</P>
<P>Other electronic sources of trials were included:<BR/> Trial registers for ongoing and registered trials - 'Current Controlled Trials' (http://www.controlled-trials.com/), 'ClinicalTrials.gov' a service of the US national Institutes of Health (http://clinicaltrials.gov/ct2/home) and 'The World Health Organisation International Trials Registry Platform search portal' (http://www.who.int/trialsearch/Default.aspx)<BR/> Citation indexes (http://scientific.thomson.com/products/sci/)</P>
<P> Conference abstracts in the ISI Web of Knowledge (http://isiwebofknowledge.com/)<BR/> LILACS database, as a source of trials from the Portuguese and Spanish speaking world (http://bases.bireme.br/cgibin/wxislind.exe/iah/online/?IsisScript=iah/iah.xis&amp;base=LILACS&amp;lang=i&amp;form=F)<BR/> ClinicalStudyResults for clinical trial results of marketed pharmaceuticals (http://www.clinicalstudyresults.org/)<BR/> PubMed (http://www.ncbi.nlm.nih.gov/pubmed/) , the random control filter for PubMed will be taken from the searching chapter of The Cochrane Handbook of Systematic.Reviews of Interventions OpenSIGLE database(http://opensigle.inist.fr/) and Google for grey literature</P>
</ELECTRONIC_SEARCHES>
<OTHER_SEARCHES MODIFIED="2009-08-11 09:58:28 +1200" MODIFIED_BY="jane clarke">
<P>The reference lists of articles retrieved by the search were hand searched and personal contact was made with experts in the field and with the manufacturers of growth hormone to obtain any additional relevant data. Any relevant journals and conference abstracts that are not covered in the MDSG register was hand-searched in liaison with the Trial Search Coordinator.</P>
</OTHER_SEARCHES>
</SEARCH_METHODS>
<DATA_COLLECTION MODIFIED="2009-08-11 10:00:41 +1200" MODIFIED_BY="jane clarke">
<P>Data collection and analysis was conducted in accordance with the Cochrane Handbook for Systematic Reviews of Interventions (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>).</P>
<STUDY_SELECTION MODIFIED="2009-08-11 09:58:56 +1200" MODIFIED_BY="jane clarke">
<P>One review author scanned retrieved searches for relevant titles and abstracts . The full text of all potentially eligible studies were retrieved. Two review authors independently examined the full text articles for compliance with the inclusion criteria and elected studies eligible for inclusion in the review. Authors corresponded with study investigators to clarify study eligibility (for example, with respect to participant eligibility criteria and allocation method). Disagreements as to study eligibility was resolved by discussion with a third author (AW).</P>
</STUDY_SELECTION>
<DATA_EXTRACTION MODIFIED="2009-08-11 09:59:06 +1200" MODIFIED_BY="jane clarke">
<P>Data was extracted from eligible studies using a data extraction form designed and pilot-tested by the authors. Where studies have multiple publications, the main trial report was used as the reference and additional details supplemented from secondary papers. Review authors corresponded with study investigators in order to resolve data queries.Two review authors (one a methodologist and one a topic area specialist) independently extracted the data and any disagreement between these reviewer authors was resolved by a third review author (AW).</P>
</DATA_EXTRACTION>
<QUALITY_ASSESSMENT MODIFIED="2009-08-11 09:59:20 +1200" MODIFIED_BY="jane clarke">
<P>The included studies were assessed for risk of bias using the Cochrane risk of bias assessment tool to assess: sequence generation; allocation concealment; blinding of participants, providers and outcome assessors; completeness of outcome data; selective outcome reporting; and other potential sources of bias. Two authors assessed these six domains, with any disagreements resolved by discussion with a third author (AW). The conclusions are presented in the Risk of Bias table and incorporated into the interpretation of review findings by means of sensitivity analyses (see below). Where identified studies failed to report the primary outcomes of live birth, but did report secondary outcomes such as clinical pregnancy, informal assessment was undertaken as to whether those reporting the primary outcomes have typical values of the secondary outcomes.</P>
</QUALITY_ASSESSMENT>
<EFFECT_MEASURES MODIFIED="2009-08-11 09:59:31 +1200" MODIFIED_BY="jane clarke">
<P>For dichotomous data the numbers of events in the control and intervention groups of each study was used to calculate Peto odds ratios. For continuous data standard mean differences between treatment groups was calculated if all studies report exactly the same outcomes. If similar outcomes are reported on different scales the standardised mean difference was calculated. Ordinal data was treated as continuous data. 95% confidence intervals were presented for all outcomes.</P>
</EFFECT_MEASURES>
<UNIT_OF_ANALYSIS MODIFIED="2009-08-11 09:59:40 +1200" MODIFIED_BY="jane clarke">
<P>The primary analysis was per woman randomised. Multiple live births (e.g. twins or triplets) will be counted as one live birth event.</P>
</UNIT_OF_ANALYSIS>
<MISSING_DATA MODIFIED="2009-08-11 09:59:52 +1200" MODIFIED_BY="jane clarke">
<P>The data was analysed on an intention-to-treat basis as far as possible and attempts were made to obtain missing data from the original investigators. Where these are unobtainable, imputation of individual values was undertaken for the primary outcomes only. Live births were assumed not to have occurred in participants with unreported outcomes. When studies reported sufficient detail to calculate mean differences but no information on associated standard deviation (SD), the outcome will be assumed to have standard deviation equal to the highest SD from other studies within the same analysis. For other outcomes, only the available data was analysed. Any imputation undertaken was subjected to sensitivity analysis (see below).</P>
</MISSING_DATA>
<HETEROGENEITY_ASSESSMENT MODIFIED="2009-08-11 10:00:02 +1200" MODIFIED_BY="jane clarke">
<P>The authors considered whether the clinical and methodological characteristics of the included studies were sufficiently similar for meta-analysis to provide a meaningful summary. Statistical heterogeneity was assessed by the measure of the I<SUP>2</SUP>. An I<SUP>2 </SUP>measurement greater than 50% indicates substantial heterogeneity (<LINK REF="REF-Higgins-2008" TYPE="REFERENCE">Higgins 2008</LINK>) and where present was addressed through sensitivity and/or subgroup analysis.</P>
</HETEROGENEITY_ASSESSMENT>
<BIAS_ASSESSMENT MODIFIED="2009-08-11 10:00:09 +1200" MODIFIED_BY="jane clarke">
<P>In view of the difficulty in detecting and correcting for publication bias and other reporting biases, we aimed to minimise their potential impact by ensuring a comprehensive search for eligible studies and by being alert for duplication of data.</P>
</BIAS_ASSESSMENT>
<DATA_SYNTHESIS MODIFIED="2009-08-11 10:00:17 +1200" MODIFIED_BY="jane clarke">
<P>The data from primary studies was combined using fixed effect models in the following comparisons:<BR/>
</P>
<P>1. Routine use of adjuvant growth hormone in IVF protocols.</P>
<P>2. Non-routine use of adjuvant growth hormone in IVF protocols in poor responders as defined by the study.</P>
</DATA_SYNTHESIS>
<SUBGROUP_ANALYSIS MODIFIED="2009-08-11 10:00:31 +1200" MODIFIED_BY="jane clarke">
<P>Subgroup analyses was conducted in the second comparison to determine the evidence within the following sub-groups:<BR/>1. Sub-optimal response following controlled ovarian stimulation.</P>
<P>2. Poor ovarian reserve as demonstrated by abnormal ovarian reserve tests.</P>
</SUBGROUP_ANALYSIS>
<SENSITIVITY_ANALYSIS MODIFIED="2009-08-11 10:00:41 +1200" MODIFIED_BY="jane clarke">
<P>Sensitivity analyses were conducted for the primary outcomes to determine whether the conclusions are robust to arbitrary decisions made regarding the eligibility and analysis. These analyses considered whether conclusions would have differed if:<BR/>1. Eligibility were restricted to studies without high risk of bias;<BR/>2. Studies with outlying results had been excluded;<BR/>3. Alternative imputation strategies had been adopted;<BR/>4. A random effects model had been adopted.</P>
</SENSITIVITY_ANALYSIS>
</DATA_COLLECTION>
</METHODS>
<RESULTS MODIFIED="2009-08-11 14:21:53 +1200" MODIFIED_BY="Julie A Brown">
<STUDY_DESCRIPTION MODIFIED="2009-08-11 14:21:09 +1200" MODIFIED_BY="Julie A Brown">
<SEARCH_RESULTS MODIFIED="2009-08-11 10:01:32 +1200" MODIFIED_BY="jane clarke">
<P>Twenty-three randomised controlled trials were identified from the search strategy, ten of which were included in the meta-analysis.</P>
</SEARCH_RESULTS>
<INCLUDED_STUDIES_DESCR MODIFIED="2009-08-11 14:21:09 +1200" MODIFIED_BY="Julie A Brown">
<P>Ten trials were included in the meta-analysis. These are presented as 13 sets of data (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Dor-1995" TYPE="STUDY">Dor 1995</LINK>; <LINK REF="STD-Hazout-2003" TYPE="STUDY">Hazout 2003</LINK>; <LINK REF="STD-Hazout-2003-4-IU" TYPE="STUDY">Hazout 2003 4 IU</LINK>; <LINK REF="STD-Hazout-2003-8-IU" TYPE="STUDY">Hazout 2003 8 IU</LINK>; <LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>;<LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK> ;<LINK REF="STD-Suikkari-1996-12-IU" TYPE="STUDY">Suikkari 1996 12 IU</LINK>; <LINK REF="STD-Suikkari-1996-4-IU" TYPE="STUDY">Suikkari 1996 4 IU</LINK>; <LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>; <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK>;<LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>; <LINK REF="STD-Zhuang-1994" TYPE="STUDY">Zhuang 1994</LINK>).  Further descriptive details about the included studies are provided in <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table.  All included trails were published reports (full papers or conference abstracts). </P>
<P>
<B>Routine use of growth hormone as an adjuvant in IVF protocols</B>
</P>
<P>Two trials concerned the routine use of growth hormone as an adjuvant in IVF protocols (<LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>). </P>
<P>
<B>Non-routine use of growth hormone as an adjuvant in IVF protocols in women considered poor responders</B>
</P>
<P>The remaining eight trials considered the non-routine use of adjuvant growth hormone in IVF protocols for subfertile couples subgrouped as:-</P>
<P>1. Poor responders as described by the study (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Dor-1995" TYPE="STUDY">Dor 1995</LINK>; <LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>; <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>; <LINK REF="STD-Hazout-2003" TYPE="STUDY">Hazout 2003</LINK>; <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK>; <LINK REF="STD-Zhuang-1994" TYPE="STUDY">Zhuang 1994</LINK>).</P>
<P>2. Poor responders because of previous sub-optimal response following controlled ovarian stimulation (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Dor-1995" TYPE="STUDY">Dor 1995</LINK>; <LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>; <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>).</P>
<P>3. Poor responders because of poor ovarian reserve as demonstrated by abnormal ovarian reserve tests - no trials identified.</P>
<P>
<B>Participants</B>
</P>
<P>Ten trials with a total of 440 subfertile couples were included in the meta-analysis.  The number of couples included in each trial ranged from 14 (<LINK REF="STD-Dor-1995" TYPE="STUDY">Dor 1995</LINK>) to 61 (<LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>).  All studies detailed the age ranges and included women aged 30 to 40 years old with exception of <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK> who included women aged forty years or older. Exclusion criteria were not stated in <LINK REF="STD-Dor-1995" TYPE="STUDY">Dor 1995</LINK>, <LINK REF="STD-Hazout-2003" TYPE="STUDY">Hazout 2003</LINK>, <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>, <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>, <LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK> and <LINK REF="STD-Zhuang-1994" TYPE="STUDY">Zhuang 1994</LINK>.  The remaining trials based their exclusion criteria on serum FSH concentrations (<LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>; <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK>), obesity (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>), ovarian pathology (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>), endometriosis (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>), severe intercurrent illness (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>) and unsatisfactory sperm quality (<LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK>). </P>
<P>
<B>Interventions</B>
</P>
<P>There was no consistency as to the dose or timing of growth hormone administration (Please see <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table). The dose of growth hormone ranged from 8IU (<LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK>) to 24IU (<LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>).  Both <LINK REF="STD-Hazout-2003" TYPE="STUDY">Hazout 2003</LINK> and <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK> conducted a multi-arm trail comparing two different doses of growth hormone to a control arm.  For the purposes of comparison the separate arms were allocated two different study IDs.  The timing of growth hormone administration varied between studies from daily administration to alternate days.</P>
<P>
<B>Outcomes</B>
</P>
<P>
<I>Primary outcome measure</I>
</P>
<P>Live birth rates were reported by seven of the included trials (<LINK REF="STD-Dor-1995" TYPE="STUDY">Dor 1995</LINK>; <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>; <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK>; <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>; <LINK REF="STD-Zhuang-1994" TYPE="STUDY">Zhuang 1994</LINK>).</P>
<P>
<I>Secondary outcomes measures</I>
</P>
<P>Pregnancy rates were reported by eight of the included trials (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Hazout-2003" TYPE="STUDY">Hazout 2003</LINK>; <LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>; <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>; <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>; <LINK REF="STD-Zhuang-1994" TYPE="STUDY">Zhuang 1994</LINK>) .  Two trials reported the number of oocytes retrieved per woman (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>).  Three trials reported the embryo transfer rate (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>; <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>).  Two trials reported the mean number of ampoules of gonadotrophin used per woman randomised (<LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>).  Adverse effects were reported by four of the trials (<LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>; <LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>).</P>
</INCLUDED_STUDIES_DESCR>
<EXCLUDED_STUDIES_DESCR MODIFIED="2009-08-11 13:09:01 +1200" MODIFIED_BY="Julie A Brown">
<P>Thirteen trials were excluded outlined in the <LINK TAG="CHARACTERISTICS_OF_EXCLUDED_STUDIES" TYPE="SECTION">Characteristics of excluded studies</LINK> table. Six trials were excluded because the participants did not undergo IVF (<LINK REF="STD-Blumenfeld-1994" TYPE="STUDY">Blumenfeld 1994</LINK>; <LINK REF="STD-Busacca-1996" TYPE="STUDY">Busacca 1996</LINK>; <LINK REF="STD-Homburg-1990b" TYPE="STUDY">Homburg 1990b</LINK>; <LINK REF="STD-Homburg-1995" TYPE="STUDY">Homburg 1995</LINK>; <LINK REF="STD-Jacobs-1995" TYPE="STUDY">Jacobs 1995</LINK>; <LINK REF="STD-Landolfi-1994" TYPE="STUDY">Landolfi 1994;</LINK> <LINK REF="STD-Tulandi-1993" TYPE="STUDY">Tulandi 1993</LINK>). A further trial were excluded because growth hormone was not the intervention (<LINK REF="STD-Howles-1999" TYPE="STUDY">Howles 1999</LINK>; <LINK REF="STD-Schoolcraft-1997" TYPE="STUDY">Schoolcraft 1997</LINK>). Three trials were excluded because the study was not truly randomised (<LINK REF="STD-Homburg-1990" TYPE="STUDY">Homburg 1990</LINK>; <LINK REF="STD-Owen-1991b" TYPE="STUDY">Owen 1991b</LINK>; <LINK REF="STD-Rinehart-1999" TYPE="STUDY">Rinehart 1999</LINK>).</P>
</EXCLUDED_STUDIES_DESCR>
</STUDY_DESCRIPTION>
<STUDY_QUALITY MODIFIED="2009-08-11 13:09:42 +1200" MODIFIED_BY="Julie A Brown">
<P>Please refer to <LINK TAG="CHARACTERISTICS_OF_INCLUDED_STUDIES" TYPE="SECTION">Characteristics of included studies</LINK> table, <LINK REF="FIG-01" TYPE="FIGURE">Figure 1</LINK> and <LINK REF="FIG-02" TYPE="FIGURE">Figure 2</LINK>.</P>
<ALLOCATION MODIFIED="2009-08-11 10:01:59 +1200" MODIFIED_BY="jane clarke">
<P>The method of randomisation was clearly stated in five trials (<LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>; <LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>, <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK>, <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK> &amp; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>).  The method of randomisation was unclear in the remaining trails.  Allocation concealment was unclear in all the included trails, except <LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>, <LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>, <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK> and <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>. </P>
</ALLOCATION>
<BLINDING MODIFIED="2009-08-11 10:02:08 +1200" MODIFIED_BY="jane clarke">
<P>One trial (<LINK REF="STD-Zhuang-1994" TYPE="STUDY">Zhuang 1994</LINK>) reported single blinding, seven trials were double blinded (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Dor-1995" TYPE="STUDY">Dor 1995</LINK>; <LINK REF="STD-Hazout-2003" TYPE="STUDY">Hazout 2003</LINK>; <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>; <LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>; <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK>) and a two trials reported triple-blinded (<LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>).</P>
</BLINDING>
<EXCLUSIONS MODIFIED="2009-08-11 13:09:42 +1200" MODIFIED_BY="Julie A Brown">
<P>Two women were lost to follow up in the <LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK> study and four women were lost to follow up in the <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK> study.  The remaining trials reported no losses. Several study authors replied to requests for additional information including <LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>, <LINK REF="STD-Dor-1995" TYPE="STUDY">Dor 1995</LINK>, <LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>, <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK> and <LINK REF="STD-Zhuang-1994" TYPE="STUDY">Zhuang 1994</LINK>.</P>
</EXCLUSIONS>
<SELECTIVE_REPORTING MODIFIED="2009-08-11 10:02:22 +1200" MODIFIED_BY="jane clarke">
<P>No selective reporting was identified.</P>
</SELECTIVE_REPORTING>
<OTHER_BIAS_SOURCES MODIFIED="2009-08-11 10:02:31 +1200" MODIFIED_BY="jane clarke">
<P>A number of trials received a free supply of growth hormone from the manufacture including <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>, <LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK> and <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>.  One trial reported a withdrawal or cycle cancellation rate greater than 10% of participants (<LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>). <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK> did not describe the nature of the placebo.</P>
</OTHER_BIAS_SOURCES>
</STUDY_QUALITY>
<INTERVENTION_EFFECTS MODIFIED="2009-08-11 14:21:53 +1200" MODIFIED_BY="Julie A Brown">
<P>The effects of adjuvant growth hormone in IVF protocols are reported in the following populations:-</P>
<P>1. Women who are not considered poor responders.</P>
<P>2. Women who are considered poor responders as defined by the study.</P>
<P>3. Women who are considered poor responders because of a previous sub-optimal response following controlled ovarian stimulation.</P>
<SUBSECTION>
<HEADING LEVEL="3">The use of adjuvant growth hormone in IVF protocols in women who are not considered poor responders.</HEADING>
<P>
<U>Main outcome measure</U>
<BR/>
</P>
<P>
<I>
<U>Live birth rate per woman randomised</U>
</I>
</P>
<P>Two trials reported the live birth rate per woman randomised (<LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>). Meta-analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to standard IVF protocols OR 1.32, 95% CI 0.40 to 4.43 ; 80 participants , 2 trials <LINK REF="CMP-001.01" TYPE="ANALYSIS">Analysis 1.1</LINK> (<LINK REF="FIG-03" TYPE="FIGURE">Figure 3</LINK>).</P>
<P>
<U>Additional outcomes measures<BR/>
</U>
</P>
<P>
<I>
<U>Pregnancy rate per woman randomised</U>
</I>
</P>
<P>One trial reported the pregnancy rate per woman randomised (<LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>). Analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to standard IVF protocols OR 1.78, 95% CI 0.49 to 6.50 ; 42 participants , 1 trials , <LINK REF="CMP-001.02" TYPE="ANALYSIS">Analysis 1.2</LINK> (<LINK REF="FIG-04" TYPE="FIGURE">Figure 4</LINK>).</P>
<P>
<I>
<U>Oocytes retrieved per woman randomised.</U>
</I>
</P>
<P>One trial reported the live birth rate per woman randomised (<LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>). Analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to standard IVF protocols OR 2.86, 95% CI 0.11 to 74.31 ; 42 participants , 1 trial <LINK REF="CMP-001.03" TYPE="ANALYSIS">Analysis 1.3</LINK> (<LINK REF="FIG-05" TYPE="FIGURE">Figure 5</LINK>).</P>
<P>
<I>
<U>Embryo transfer per woman randomised</U>
</I>
</P>
<P>One trial reported the number of embryos transferred per woman randomised (<LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>). Analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to standard IVF protocols OR 7.36, 95% CI 0.36 to 151.91 ; 42 participants , 1 trial <LINK REF="CMP-001.04" TYPE="ANALYSIS">Analysis 1.4</LINK> (<LINK REF="FIG-06" TYPE="FIGURE">Figure 6</LINK>).</P>
<P>
<I>
<U>Mean ampoules of gonadotrophin used.</U>
</I>
</P>
<P>Two trials (<LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>) reported the mean number of ampoules of gonadotrophin used per woman randomised. Meta-analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to standard IVF protocols OR 0.18, 95% CI -1.53 to 1.87 ; 80 participants , 2 trials <LINK REF="CMP-001.05" TYPE="ANALYSIS">Analysis 1.5</LINK> (<LINK REF="FIG-07" TYPE="FIGURE">Figure 7</LINK>).</P>
<P>
<I>
<U>Adverse events</U>
</I>
</P>
<P>Two trials reported the occurrence of adverse events (<LINK REF="STD-Tapanainen-1992" TYPE="STUDY">Tapanainen 1992</LINK>; <LINK REF="STD-Younis-1992" TYPE="STUDY">Younis 1992</LINK>). Meta-analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to standard IVF protocols OR 0.62, 95% CI 0.18 to 2.15 ; 80 participants , 2 trials <LINK REF="CMP-001.06" TYPE="ANALYSIS">Analysis 1.6</LINK> (<LINK REF="FIG-08" TYPE="FIGURE">Figure 8</LINK>).</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">The use of adjuvant growth hormone in IVF protocols in women who are considered poor responders as defined by the included study.</HEADING>
<P>
<U>Main outcome measure</U>
<BR/>
</P>
<P>
<I>
<U>Live birth rate per woman randomised</U>
</I>
</P>
<P>Four trials reported the live birth rate per woman randomised (<LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Suikkari-1996-4-IU" TYPE="STUDY">Suikkari 1996 4 IU</LINK>; <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005;</LINK> <LINK REF="STD-Zhuang-1994" TYPE="STUDY">Zhuang 1994</LINK>). Meta-analysis demonstrated a statistically significant difference favouring the use growth hormone adjuvant in IVF protocols when compared to IVF protocols in women with a poor prognosis as defined by the included study OR 5.39, 95% CI 1.89 to 15.35 ; 165 participants , 4 trials , <LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK> (<LINK REF="FIG-09" TYPE="FIGURE">Figure 9</LINK>).</P>
<P>
<U>Additional outcomes measures</U>
</P>
<P>
<I>
<U>Pregnancy rate per woman randomised</U>
</I>
</P>
<P>Seven of the trials reported the pregnancy birth rate per woman randomised (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Hazout-2003-4-IU" TYPE="STUDY">Hazout 2003 4 IU</LINK>; <LINK REF="STD-Hazout-2003-8-IU" TYPE="STUDY">Hazout 2003 8 IU</LINK>; <LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>; <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Suikkari-1996-4-IU" TYPE="STUDY">Suikkari 1996 4 IU</LINK>; <LINK REF="STD-Tesarik-2005" TYPE="STUDY">Tesarik 2005</LINK>; <LINK REF="STD-Zhuang-1994" TYPE="STUDY">Zhuang 1994</LINK>). Meta-analysis demonstrated a statistically significant difference favouring the use growth hormone adjuvant in IVF protocols when compared to IVF protocols in women with a poor prognosis as defined by the included study OR 3.28, 95% CI 1.74 to 6.20 ; 279 participants , 7 trials , <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK> (<LINK REF="FIG-10" TYPE="FIGURE">Figure 10</LINK>).</P>
<P>
<I>
<U>Oocytes retrieved per woman randomised</U>
</I>
</P>
<P>One trial reported the oocytes retrieved per woman randomised (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>). Analysis could not be performed because the same number of events occurred in each group, and the groups involved the same number of couples <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK> (<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>).</P>
<P>
<I>
<U>Embryo transfer per woman randomised</U>
</I>
</P>
<P>Two trials reported the number of embryos transferred per woman randomised (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Suikkari-1996-4-IU" TYPE="STUDY">Suikkari 1996 4 IU</LINK>; <LINK REF="STD-Suikkari-1996-12-IU" TYPE="STUDY">Suikkari 1996 12 IU</LINK>). Meta-analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to IVF protocols in women with a sub-optimal response following controlled ovarian stimulation OR 2.01, 95% CI 0.38 to 10.78 ; 40 participants , 2 trials , <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK> (<LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>).</P>
<P>
<I>
<U>Adverse events</U>
</I>
</P>
<P>One trial reported the oocytes retrieved per woman randomised (<LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>). Analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to IVF protocols in women with a sub-optimal response following controlled ovarian stimulation OR 2.00, 95% CI 0.16 to 25.40 ; 116 participants , 1 trial , <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK> (<LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK>).</P>
<P>
<U>Sensitivity Analysis</U>
</P>
<P>One trial reported a withdrawal or cycle cancellation rate greater than 10% of participants (<LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>). A sensitivity analysis was performed to detect whether the inclusion of this randomised controlled trials affected the results. There was no difference in results when the meta-analysis was re-calculated.</P>
</SUBSECTION>
<SUBSECTION>
<HEADING LEVEL="3">The use of adjuvant growth hormone in IVF protocols in women who are considered poor responders because of a previous s<I>ub-optimal response following controlled ovarian stimulation</I>
</HEADING>
<P>
<U>Main outcome measure</U>
<BR/>
</P>
<P>
<I>
<U>Live birth rate per woman randomised</U>
</I>
</P>
<P>Two trials reported the live birth rate per woman randomised (<LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Suikkari-1996-4-IU" TYPE="STUDY">Suikkari 1996 4 IU</LINK>). Meta-analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to IVF protocols in women with a sub-optimal response following controlled ovarian stimulation OR 5.81, 95% CI 0.67 to 50.39 ; 38 participants , 2 trials , <LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK> (<LINK REF="FIG-11" TYPE="FIGURE">Figure 11</LINK>).</P>
<P>
<U>Additional outcomes measures</U>
</P>
<P>
<I>
<U>Pregnancy rate per woman randomised</U>
</I>
</P>
<P>Four of the trials reported the pregnancy birth rate per woman randomised (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Kueuk-2008" TYPE="STUDY">Kueuk 2008</LINK>; <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>; <LINK REF="STD-Suikkari-1996-4-IU" TYPE="STUDY">Suikkari 1996 4 IU</LINK>). Meta-analysis demonstrated a statistically significant difference favouring the use growth hormone adjuvant in IVF protocols when compared to IVF protocols in women with a sub-optimal response following controlled ovarian stimulation OR 2.58, 95% CI 1.03 to 6.46 ; 116 participants , 4 trials , <LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK> (<LINK REF="FIG-12" TYPE="FIGURE">Figure 12</LINK>).</P>
<P>
<I>
<U>Oocytes retrieved per woman randomised</U>
</I>
</P>
<P>One trial reported the oocytes retrieved per woman randomised (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>). Analysis could not be performed because the same number of events occurred in each group, and the groups involved the same number of couples <LINK REF="CMP-003.03" TYPE="ANALYSIS">Analysis 3.3</LINK> (<LINK REF="FIG-13" TYPE="FIGURE">Figure 13</LINK>).</P>
<P>
<I>
<U>Embryo transfer per woman randomised</U>
</I>
</P>
<P>Two trials reported the number of embryos transferred per woman randomised (<LINK REF="STD-Bergh-1994" TYPE="STUDY">Bergh 1994</LINK>; <LINK REF="STD-Suikkari-1996-4-IU" TYPE="STUDY">Suikkari 1996 4 IU</LINK>; <LINK REF="STD-Suikkari-1996-12-IU" TYPE="STUDY">Suikkari 1996 12 IU</LINK>). Meta-analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to IVF protocols in women with a sub-optimal response following controlled ovarian stimulation OR 2.01, 95% CI 0.38 to 10.78 ; 40 participants , 2 trials , <LINK REF="CMP-003.04" TYPE="ANALYSIS">Analysis 3.4</LINK> (<LINK REF="FIG-14" TYPE="FIGURE">Figure 14</LINK>).</P>
<P>
<I>
<U>Adverse events</U>
</I>
</P>
<P>One trial reported the oocytes retrieved per woman randomised (<LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>). Analysis demonstrated no difference in the use growth hormone adjuvant in IVF protocols when compared to IVF protocols in women with a sub-optimal response following controlled ovarian stimulation OR 2.00, 95% CI 0.16 to 25.40 ; 116 participants , 1 trial , <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK> (<LINK REF="FIG-15" TYPE="FIGURE">Figure 15</LINK>).</P>
<P>
<U>Sensitivity Analysis</U>
</P>
<P>One trial reported a withdrawal or cycle cancellation rate greater than 10% of participants (<LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>). A sensitivity analysis was performed to detect whether the inclusion of this randomised controlled trials affected the results. There was no difference in results when the meta-analysis was re-calculated.</P>
</SUBSECTION>
</INTERVENTION_EFFECTS>
</RESULTS>
<DISCUSSION MODIFIED="2009-08-11 14:22:35 +1200" MODIFIED_BY="Julie A Brown">
<SUMMARY_OF_RESULTS MODIFIED="2009-08-11 14:21:59 +1200" MODIFIED_BY="Julie A Brown">
<P>This review was undertaken to establish the role of growth hormone adjuvant therapy for IVF in improving IVF outcomes particularly in those women who are considered poor responders. Results of this meta-analysis demonstrated no difference in IVF outcome measures and adverse events in the routine use of growth hormone adjuvant therapy in IVF. However, meta-analysis demonstrated a statistically significant difference in both live birth rates and pregnancy rates favouring the use of growth hormone adjuvant therapy in IVF in women who are considered poor responders without increasing adverse events (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>, <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). Although these results have to be interpreted with caution, the trials included in the meta-analysis were few and of small sample size.</P>
<P>Defining which sub-group or sub-groups of poor responder benefited the most from growth hormone adjuvant therapy in IVF proved challenging due to the diverse definitions of poor responder used by the included studies. Sub-group analysis demonstrated a statistically significant difference in pregnancy rates favouring the use of growth hormone adjuvant in IVF in women who are considered poor responders because of previous sub-optimal response following controlled ovarian stimulation without increasing adverse events. Although these results have to be interpreted with caution, the trials included in the meta-analysis were few and of small sample size. (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>, <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). However, meta-analysis demonstrated no difference in the other IVF outcome measures, including live birth rate, in the use of growth hormone adjuvant in IVF in these women (<LINK REF="CMP-003.01" TYPE="ANALYSIS">Analysis 3.1</LINK>).</P>
</SUMMARY_OF_RESULTS>
<APPLICABILITY_OF_FINDINGS MODIFIED="2009-08-11 14:22:08 +1200" MODIFIED_BY="Julie A Brown">
<P>Meta-analysis demonstrated a statistically significant difference in both live birth rates and pregnancy rates favouring the use of growth hormone adjuvant in IVF in women who are considered poor responders without increasing adverse events (<LINK REF="CMP-002.01" TYPE="ANALYSIS">Analysis 2.1</LINK>, <LINK REF="CMP-002.02" TYPE="ANALYSIS">Analysis 2.2</LINK>, <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). Sub-group analysis demonstrated a statistically significant difference in pregnancy rates favouring the use of growth hormone adjuvant in IVF in women who are considered poor responders because of previous sub-optimal response following controlled ovarian stimulation without increasing adverse events (<LINK REF="CMP-003.02" TYPE="ANALYSIS">Analysis 3.2</LINK>, <LINK REF="CMP-003.05" TYPE="ANALYSIS">Analysis 3.5</LINK>). The width of the confidence interval should be taken into account when considering the results. The wide confidence interval emphasises the lack of available evidence, the included trials were few in number and of small sample size for the primary outcome, live birth rates, in the sub-group analysis.</P>
<P>Adverse effects were also considered as a secondary outcome. Frequency of reporting of adverse effects varied between the trials and different adverse effects were recorded. In general adverse effects were not well documented making the meta-analysis result fairly unreliable as emphasised by the wide confidence intervals. For those that were documented, growth hormone adjuvant in IVF protocols did not significantly reduce the incidence of any of the adverse effects in either group.</P>
<P>The causative factors for poor response to controlled controlled ovarian hyperstimulation are not well described in the literature. Consequently the definitions of a 'poor responder' are varied ranging from age to poor responders to gonadotrophin stimulation on previous IVF cycles. Therefore the inclusion criteria of the included trials varied greatly. Therefore we have been unable to identify the particular sub-group of poor responders who would benefit the most from growth hormone augmentation in IVF protocols in terms of live birth rates.</P>
</APPLICABILITY_OF_FINDINGS>
<QUALITY_OF_EVIDENCE MODIFIED="2009-08-11 13:25:32 +1200" MODIFIED_BY="Julie A Brown">
<P>Of the ten randomised controlled trials included in the review differences in participant number, cause of subfertility, treatment protocol and outcomes measured all varied considerably between the trials. There was no uniformity of dose and timing of the intervention. A large scale trial with a standardised treatment protocol and intervention protocol is required (Please refer to <LINK TAG="IMPLICATIONS_RESEARCH" TYPE="SECTION">Implications for research</LINK> section).</P>
<P>There was a lack of large high quality trials comparing growth hormone to placebo in ovarian stimulation protocols in IVF cycles. If a new large randomised controlled trial was performed the results of this review could be significantly different.</P>
</QUALITY_OF_EVIDENCE>
<POTENTIAL_BIASES MODIFIED="2009-08-11 14:22:13 +1200" MODIFIED_BY="Julie A Brown">
<P>Critical to the limitation of bias in these included randomised controlled trials are the randomisation method and allocation concealment strategy deployed, both of which provide similar comparison groups achieving a balance of both known and unknown factors that may influence the outcome. Six of the ten included trials did not state explicitly the method of randomisation used. Failure to report how women were randomised does not allow us to evaluate the adequacy of the method deployed. Furthermore, seven of the ten included randomised controlled trials did not state a method of allocation concealment. This could undermine further the quality of the included randomised controlled trial. With poor methods of concealing the allocation, knowledge of the treatment codes may be gained in advance, increasing the likelihood of selection bias (<LINK REF="REF-Li-2005" TYPE="REFERENCE">Li 2005</LINK>).</P>
<P>One trial reported a withdrawal or cycle cancellation rate greater than 10% of participants (<LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>). A sensitivity analysis was performed to detect whether the inclusion of this randomised controlled trial affected the results. There was no difference in results when the meta-analysis was re-calculated.</P>
<P>
<LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK> did not describe the nature of the placebo which could have lead to bias if the placebo had an action mechanism similar to growth hormone</P>
</POTENTIAL_BIASES>
<AGREEMENT MODIFIED="2009-08-11 14:22:35 +1200" MODIFIED_BY="Julie A Brown">
<P>Currently no national or international guidelines recommend the routine use of growth hormone augmentation in IVF protocols. However a recent systematic review and meta-analysis concerning the evaluation of strategies to improve the pregnancy rates in poor responders undergoing IVF concluded that there was some evidence to suggest the addition of growth hormone could improve live birth rates but further research was required (<LINK REF="REF-Kyrou-2009" TYPE="REFERENCE">Kyrou 2009</LINK>). Kyrou and colleagues analysis and conclusions broadly agree with our own.</P>
<P>Other studies have reported mixed results. Rinehart and colleagues reported that growth hormone did not significantly increase the pregnancy rates for women who were defined as 'poor responders' to gonadotrophin stimulation on previous IVF cycles. The study, which was non-randomised in design, and defined a poor responder as one whose follicles did not reach 18mm in diameter or an E2 of less than 500 pg/ml (<LINK REF="STD-Rinehart-1999" TYPE="STUDY">Rinehart 1999</LINK>). In a cross-over trial Blumenfeld 1996 (<LINK REF="REF-Blumenfeld-1996" TYPE="REFERENCE">Blumenfeld 1996</LINK>) examined the role of growth hormone augmentation in poor responders to gonadotrophin stimulation on previous IVF cycles. Interestingly the study concluded that the addition of growth hormone was only beneficial in terms of pregnancy and live birth rates in women who were not 'endocrinologically normal' as illustrated by being identified as clonidine positive.</P>
<P>Other studies have evaluated the potential for the use of growth hormone releasing factor. Growth hormone releasing factor may also have a role in ovulation induction for IVF. Pituitary growth hormone secretion is controlled by growth hormone releasing factor which may also have a direct effect on the ovary. A pilot study demonstrated that growth hormone releasing factor was associated with improvement in ovarian response and resulted in slight increases in recruited follicles and retrieved oocytes (<LINK REF="STD-Hughes-1994" TYPE="STUDY">Hughes 1994</LINK>). Growth hormone releasing factor seems to have a similar effect as growth hormone on ovarian response (<LINK REF="STD-Howles-1999" TYPE="STUDY">Howles 1999</LINK>). Howles and colleagues performed a randomised controlled trial and reported that growth hormone releasing factor did not significantly increase the pregnancy or live birth rates for women who demonstrate as poor responders to gonadotrophin stimulation on previous IVF cycles.</P>
</AGREEMENT>
</DISCUSSION>
<CONCLUSIONS MODIFIED="2009-08-11 13:27:57 +1200" MODIFIED_BY="Julie A Brown">
<IMPLICATIONS_PRACTICE MODIFIED="2009-08-11 13:27:47 +1200" MODIFIED_BY="Julie A Brown">
<P>In women who are not considered poor responders undergoing in IVF there is no evidence from randomised controlled trials to support the use of growth hormone. In women who are considered poor responders the use of growth hormone has been shown to significantly improve live birth and pregnancy rates. Although the exact sub-group of poor responders who would benefit from growth hormone augmentation needs to be identified. The result needs to be interpreted with caution, the included trials were few in number and small with significant clinical heterogeneity.</P>
</IMPLICATIONS_PRACTICE>
<IMPLICATIONS_RESEARCH MODIFIED="2009-08-11 13:27:57 +1200" MODIFIED_BY="Julie A Brown">
<P>With regards to women who are known poor responders to IVF, a multi-centre randomised double blinded trial is warranted to investigate the effect of growth hormone augmentation. Key elements of design should include power calculation to ensure the minimum number of participants needed for a significant result are included, the standardisation of controlled controlled ovarian hyperstimulation protocols, dose of growth hormone and the definition of a poor responder - &lt;4 oocytes retrieved in a previous IVF attempt might be appropriate. The primary outcome of live birth rate should be measured. Only by considering such outcomes can this therapy be truly tested. Also, adverse effects, for example OHSS and miscarriage, should be routinely reported. Given the high hormone cost of treatment, one component of this study should also be an economic evaluation.</P>
</IMPLICATIONS_RESEARCH>
</CONCLUSIONS>
</BODY>
<ACKNOWLEDGEMENTS MODIFIED="2009-08-11 10:04:04 +1200" MODIFIED_BY="jane clarke">
<P>We would like to thank the members of the Cochrane Menstrual Disorders and Subfertility Review Group based in Auckland, New Zealand, who assisted with this review.</P>
</ACKNOWLEDGEMENTS>
<CONFLICT_OF_INTEREST MODIFIED="2009-08-11 10:04:20 +1200" MODIFIED_BY="jane clarke">
<P>None known<BR/>
</P>
</CONFLICT_OF_INTEREST>
<CONTRIBUTIONS MODIFIED="2009-08-11 13:28:13 +1200" MODIFIED_BY="Julie A Brown">
<P>D Kotarba, J Kotarba, and E Hughes prepared the original version of this review published in 1995. The 2003 update of the review was prepared by K Harper and M Proctor. The 2009 update of the review was prepared by G Ahmad, J Brown, JMN Duffy and L Nardo, I Salim and AJ Watson</P>
</CONTRIBUTIONS>
<PRO_REV_DIFF MODIFIED="2009-08-11 13:28:28 +1200" MODIFIED_BY="Julie A Brown">
<P>The authors of the protocol were different from the review, additional authors were included in the 2009 update: G Ahmad, J Brown, JMN Duffy, L Nardo, I Salim and AJ Watson.</P>
</PRO_REV_DIFF>
<PUBLIC_NOTES MODIFIED="2008-11-19 03:03:41 +1300" MODIFIED_BY="James M N Duffy"/>
</MAIN_TEXT>
<STUDIES_AND_REFERENCES MODIFIED="2009-08-11 15:39:21 +1200" MODIFIED_BY="jane clarke">
<STUDIES MODIFIED="2009-08-11 13:01:11 +1200" MODIFIED_BY="Julie A Brown">
<INCLUDED_STUDIES MODIFIED="2009-08-11 13:01:11 +1200" MODIFIED_BY="Julie A Brown">
<STUDY DATA_SOURCE="PUB" ID="STD-Bergh-1994" MODIFIED="2009-08-03 05:07:54 +1200" MODIFIED_BY="James M N Duffy" NAME="Bergh 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergh C, Carlstrom K, Selleskog U, Hillensjo T</AU>
<TI>Effect of growth hormone on follicular fluid androgen levels in patients treated with gonadotropins before in vitro fertilization</TI>
<SO>European Journal of Endocrinology</SO>
<YR>1996</YR>
<VL>134</VL>
<PG>190-6</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Bergh C, Nilsson L, Hillensjo T, Borg G, Wikland M, Hamgerger L</AU>
<TI>Adjuvant growth hormone treatment during in vitro fertilization: a randomized, placebo-controlled study</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1994</YR>
<VL>62</VL>
<PG>113-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Dor-1995" MODIFIED="2009-08-03 05:08:00 +1200" MODIFIED_BY="James M N Duffy" NAME="Dor 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Dor J, Seidman DS, Amudia E, Bider D, Levran D, Mashiach S</AU>
<TI>Adjuvant growth hormone therapy in poor responders to in-vitro fertilization: a prospective randomized placebo-controlled double-blind study</TI>
<SO>Human Reproduction</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>40-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hazout-2003" MODIFIED="2009-08-11 13:00:14 +1200" MODIFIED_BY="Julie A Brown" NAME="Hazout 2003" YEAR="2003">
<REFERENCE MODIFIED="2009-08-11 13:00:14 +1200" MODIFIED_BY="Julie A Brown" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hazout A, Junca AM</AU>
<TI>A pilot, prospective, randomised, double blind, placebo-controlled study to compare protocols for ovarian stimulation with r-hRSH (Gonal-F) combined with two different doses of r-hGH or placebo in patients with oocyte dysmorphy undergoing ICSI</TI>
<SO>Human Reproduction</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Supplement 1</NO>
<PG>299-212</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS MODIFIED="2009-08-03 04:29:46 +1200" MODIFIED_BY="James M N Duffy"/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hazout-2003-4-IU" MODIFIED="2009-08-11 13:00:40 +1200" MODIFIED_BY="Julie A Brown" NAME="Hazout 2003 4 IU" YEAR="">
<REFERENCE MODIFIED="2009-08-11 13:00:40 +1200" MODIFIED_BY="Julie A Brown" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hazout A, Junca AM</AU>
<TI>A pilot, prospective, randomised, double blind, placebo-controlled study to compare protocols for ovarian stimulation with r-hRSH (Gonal-F) combined with two different doses of r-hGH or placebo in patients with oocyte dysmorphy undergoing ICSI</TI>
<SO>Human Reproduction</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Supplement 1</NO>
<PG>299-212</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hazout-2003-8-IU" MODIFIED="2009-08-11 13:01:11 +1200" MODIFIED_BY="Julie A Brown" NAME="Hazout 2003 8 IU" YEAR="">
<REFERENCE MODIFIED="2009-08-11 13:01:11 +1200" MODIFIED_BY="Julie A Brown" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hazout A, Junca AM</AU>
<TI>A pilot, prospective, randomised, double blind, placebo-controlled study to compare protocols for ovarian stimulation with r-hRSH (Gonal-F) combined with two different doses of r-hGH or placebo in patients with oocyte dysmorphy undergoing ICSI</TI>
<SO>Human Reproduction</SO>
<YR>2003</YR>
<VL>18</VL>
<NO>Supplement 1</NO>
<PG>299-212</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Kueuk-2008" MODIFIED="2009-08-03 05:08:09 +1200" MODIFIED_BY="James M N Duffy" NAME="Kueuk 2008" YEAR="2008">
<REFERENCE MODIFIED="2009-07-17 07:21:21 +1200" MODIFIED_BY="James M N Duffy" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Kucuk T, Kozinoglu H, Kaba A</AU>
<TI>Growth hormone co-treatment within a GnRH agonist long protocol in patients with poor ovarian response:a prospective, randomized, clinical trial</TI>
<SO>Journal of Assisted Reproduction and Genetics</SO>
<YR>2008</YR>
<VL>25</VL>
<PG>123-127</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Owen-1991" MODIFIED="2009-08-03 05:08:13 +1200" MODIFIED_BY="James M N Duffy" NAME="Owen 1991" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs HS</AU>
<TI>Growth hormone and ovulation: Is there an indication for treatment of infertile women with growth hormone?</TI>
<SO>Hormone Research</SO>
<YR>1992</YR>
<VL>38</VL>
<PG>14-21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Owen EJ, Ostergaard H, Shoham Z, Jacobs HS, Mason BA</AU>
<TI>Cotreatment with growth hormone, after pituitary suppression, for ovarian stimulation in in vitro fertilization: a randomized, double-blind, placebo-control trial</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1991</YR>
<VL>56</VL>
<PG>1104-10</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suikkari-1996" MODIFIED="2009-08-03 05:08:18 +1200" MODIFIED_BY="James M N Duffy" NAME="Suikkari 1996" YEAR="1996">
<REFERENCE NOTES="&lt;p&gt;12 IU and 4 IU&lt;/p&gt;" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suikkari AM, MacLachlan V, Koistinen R, Seppälä M, Healy DL</AU>
<TI>Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1996</YR>
<VL>65</VL>
<NO>4</NO>
<PG>800-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suikkari-1996-12-IU" MODIFIED="2009-08-03 05:07:46 +1200" MODIFIED_BY="James M N Duffy" NAME="Suikkari 1996 12 IU" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suikkari AM, MacLachlan V, Koistinen R, Seppälä M, Healy DL</AU>
<TI>Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1996</YR>
<VL>65</VL>
<NO>4</NO>
<PG>800-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Suikkari-1996-4-IU" MODIFIED="2009-08-03 05:07:40 +1200" MODIFIED_BY="James M N Duffy" NAME="Suikkari 1996 4 IU" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Suikkari AM, MacLachlan V, Koistinen R, Seppälä M, Healy DL</AU>
<TI>Double-blind placebo controlled study: human biosynthetic growth hormone for assisted reproductive technology</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1996</YR>
<VL>65</VL>
<NO>4</NO>
<PG>800-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tapanainen-1992" MODIFIED="2009-08-03 05:08:23 +1200" MODIFIED_BY="James M N Duffy" NAME="Tapanainen 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tapanainen J, Orava M, Martikainen H, Ruokonen A, Voutilainen R, Ronnberg L</AU>
<TI>Effect of growth hormone administration on human ovarian function and steroidogenic gene expression in granulosa-luteal cells</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1992</YR>
<VL>58</VL>
<PG>726-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tesarik-2005" MODIFIED="2009-08-03 05:08:27 +1200" MODIFIED_BY="James M N Duffy" NAME="Tesarik 2005" YEAR="2005">
<REFERENCE MODIFIED="2009-08-03 05:00:49 +1200" MODIFIED_BY="James M N Duffy" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tesarik J, Hazout A, Mendoza C</AU>
<TI>Improvement of delivery and live birth rates after ICSI in women aged&gt;40 years by ovarian co-stimulation with growth hormone</TI>
<SO>Human Reproduction</SO>
<YR>2005</YR>
<VL>20</VL>
<NO>9</NO>
<PG>2536-2541</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Younis-1992" MODIFIED="2009-08-03 05:08:33 +1200" MODIFIED_BY="James M N Duffy" NAME="Younis 1992" YEAR="1992">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Younis JS, Dorembus D, Simon A, Schenker JG, Koren R, Laufer N</AU>
<TI>The effect of growth hormone supplementation on in vitro fertilization outcome: a prospective randomized placebo-controlled double-blind study</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1992</YR>
<VL>58</VL>
<PG>575-80</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Younis JS, Ezra Y, Brzezinnski, Fibich T, Schenker JG, Laufer N</AU>
<TI>The effect of growth hormone on granulosa cell function during in-vitro fertilization</TI>
<SO>Human Reproduction</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>10</NO>
<PG>1588-92</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Zhuang-1994" MODIFIED="2009-08-03 05:08:37 +1200" MODIFIED_BY="James M N Duffy" NAME="Zhuang 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Zhuang GL, Wong SX, Zhou CQ</AU>
<TI>The effect of co-administration of low dosage growth hormone and gonadotropin for ovarian hyperstimulation in vitro fertilization and embryo transfer</TI>
<SO>Chung-Hua Fu Chan Ko Tsa Chih (Chinese Journal of Obstetrics and Gynaecology)</SO>
<YR>1994</YR>
<VL>29</VL>
<NO>8</NO>
<PG>471-4</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</INCLUDED_STUDIES>
<EXCLUDED_STUDIES MODIFIED="2009-08-10 08:50:05 +1200" MODIFIED_BY="James M N Duffy">
<STUDY DATA_SOURCE="PUB" ID="STD-Blumenfeld-1994" MODIFIED="2009-08-10 08:50:05 +1200" MODIFIED_BY="James M N Duffy" NAME="Blumenfeld 1994" YEAR="1994">
<REFERENCE MODIFIED="2009-07-18 10:20:18 +1200" MODIFIED_BY="James M N Duffy" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blumenfeld Z, Amit T</AU>
<TI>The role of growth hormone (GH), GH-receptor and GH-binding protein in reproduction and ovulation induction</TI>
<SO>Journal of Pediatric Endocrinology &amp; Metabolism</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>145-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-18 10:20:18 +1200" MODIFIED_BY="James M N Duffy" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blumenfeld Z, Amit T</AU>
<TI>The role of growth hormone in ovulation induction</TI>
<SO>Annals of Medicine</SO>
<YR>1994</YR>
<VL>26</VL>
<PG>249-54</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE MODIFIED="2009-07-18 10:20:18 +1200" MODIFIED_BY="James M N Duffy" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Blumenfeld Z, Dirnfeld M, Gonen Y, Abramovici H</AU>
<TI>Growth hormone co-treatment for ovulation induction may enhance conception in the co-treatment and succeeding cycles, in clonidine negative but not clonidine positive patients</TI>
<SO>Human Reproduction</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>209-13</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Busacca-1996" NAME="Busacca 1996" YEAR="1996">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Busacca M, Fusi MF, Brigante C, Bonzi V, Gonfiantini C, Vignali M et al</AU>
<TI>Use of growth hormone-releasing factor in ovulation induction in poor responders</TI>
<SO>Journal of Reproductive Medicine</SO>
<YR>1996</YR>
<VL>41</VL>
<NO>9</NO>
<PG>699-703</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homburg-1990" NAME="Homburg 1990" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homburg R, West C, Torresani T, Jacobs HS</AU>
<TI>A comparative study of single-dose growth hormone as an adjuvant to gonadotrophin treatment for ovulation induction</TI>
<SO>Clinical Endocrinology</SO>
<YR>1990</YR>
<VL>32</VL>
<PG>781-5</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homburg-1990b" NAME="Homburg 1990b" YEAR="1990">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homburg R, West C, Torresani T, Jacobs HS</AU>
<TI>Cotreatment with human growth hormone and gonadotropins for induction of ovulation: a controlled clinical trial</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1990</YR>
<VL>53</VL>
<NO>2</NO>
<PG>254-60</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Homburg-1995" NAME="Homburg 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Homburg R, Levy T, Ben-Rafael Z</AU>
<TI>Adjuvant growth hormone for induction of ovulation with gonadotrophin-releasing hormone agonist and gonadotrophins in polycystic ovary syndrome: a randomized, double-blind, placebo controlled trial</TI>
<SO>Human Reproduction</SO>
<YR>1995</YR>
<VL>10</VL>
<PG>2550-3</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Howles-1999" MODIFIED="2009-08-03 05:11:32 +1200" MODIFIED_BY="James M N Duffy" NAME="Howles 1999" YEAR="1999">
<REFERENCE MODIFIED="2009-08-03 05:11:30 +1200" MODIFIED_BY="James M N Duffy" PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Howles CM, Loumaye E, Germond M, Yates R, Brinsden P, Healy D, Bonaventura LM, Strowitzki T</AU>
<TI>Does growth hormone-releasing factor assist follicular development in poor responder patients undergoing ovarian stimulation for in-vitro fertilisation?</TI>
<SO>Human Reproduction</SO>
<YR>1999</YR>
<VL>14</VL>
<NO>8</NO>
<PG>1939-1943</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Hughes-1994" NAME="Hughes 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Huang ZH, Baxter RC, Hughes SM, Matson PL, Lieberman BA, Morris ID</AU>
<TI>Supplementary growth hormone treatment of women with poor ovarian response to exogenous gonadotrophins: changes in serum and follicular fluid insulin-like growth factor-1 (IGF-1) and IGF binding protein-3 (IGFBP-3)</TI>
<SO>Human Reproduction</SO>
<YR>1993</YR>
<VL>8</VL>
<PG>850-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes SM, Huang ZH, Morris ID, Matson PL, Buck P, Lieberman BA</AU>
<TI>A double blind cross over controlled study to evaluate the effect of human biosynthetic growth hormone on ovarian stimulation in previous IVF poor responders</TI>
<SO>Journal of Reproductive Fertility</SO>
<YR>1992</YR>
<VL>96</VL>
<PG>21</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Hughes SM, Huang ZH, Morris ID, Matson PL, Buck P, Lieberman BA</AU>
<TI>A double-blind cross-over controlled study to evaluate the effect of human biosynthetic growth hormone on ovarian stimulation in previous poor responders to in-vitro fertilization</TI>
<SO>Human Reproduction</SO>
<YR>1994</YR>
<VL>9</VL>
<PG>13-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Jacobs-1995" NAME="Jacobs 1995" YEAR="1995">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Jacobs HS, Shoham Z, Schachter M, Braat DDM, Franks S, Hamilton-Fairley D</AU>
<TI>Cotreatment with growth hormone and gonadotropin for ovulation induction in hypogonadotropic patients: A prospective, randomized, placebo-controlled, dose-response study</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1995</YR>
<VL>64</VL>
<NO>5</NO>
<PG>917-23</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Landolfi-1994" NAME="Landolfi 1994" YEAR="1994">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Landolfi L, Marra V, Gallina N</AU>
<TI>Ovulation induction with growth hormone and GnRH in polycystic ovarian disease</TI>
<SO>Rassegna Internazionale di Clinica e Terapia</SO>
<YR>1994</YR>
<VL>74</VL>
<NO>12</NO>
<PG>529-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Owen-1991b" NAME="Owen 1991b" YEAR="1991">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Owen EJ, Torresani T, West C, Mason BA, Jacobs HS</AU>
<TI>Serum and follicular fluid insulin like growth factors I and II during growth hormone co-treatment for in-vitro fertilization and embryo transfer</TI>
<SO>Clinical Endocrinology</SO>
<YR>1991</YR>
<VL>35</VL>
<PG>3217-34</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Owen EJ, West C, Mason BA, Jacobs HS</AU>
<TI>Cotreatment with growth hormone of sub-optimal responders in IVF-ET</TI>
<SO>Human Reproduction</SO>
<YR>1991</YR>
<VL>6</VL>
<PG>524-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Rinehart-1999" NAME="Rinehart 1999" YEAR="1999">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Rinehart JS</AU>
<TI>Randomized, prospective trial comparing the addition of growth hormone for the ovulation induction of "poor responders" in IVF</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1999</YR>
<VL>72</VL>
<NO>3</NO>
<PG>S91</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Schoolcraft-1997" NAME="Schoolcraft 1997" YEAR="1997">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Schoolcraft W, Schlenker T, Gee M, Stevens J, Wagley L</AU>
<TI>Improved controlled ovarian hyperstimulation in poor responder in vitro fertilization patients with a microdose follicle-stimulating hormone flare, growth hormone protocol</TI>
<SO>Fertility &amp; Sterility</SO>
<YR>1997</YR>
<VL>67</VL>
<NO>1</NO>
<PG>93-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
<STUDY DATA_SOURCE="PUB" ID="STD-Tulandi-1993" NAME="Tulandi 1993" YEAR="1993">
<REFERENCE PRIMARY="NO" TYPE="JOURNAL_ARTICLE">
<AU>Tulandi T, Falcone T, Guyda H, Hemmings R, Billiar R, Morris D</AU>
<TI>Effects of synthetic growth hormone-releasing factor in women treated with gonadotrophin</TI>
<SO>Human Reproduction</SO>
<YR>1993</YR>
<VL>8</VL>
<NO>4</NO>
<PG>525-7</PG>
<IDENTIFIERS/>
</REFERENCE>
<IDENTIFIERS/>
</STUDY>
</EXCLUDED_STUDIES>
<AWAITING_STUDIES MODIFIED="2009-08-11 11:45:14 +1200" MODIFIED_BY="jane clarke"/>
<ONGOING_STUDIES/>
</STUDIES>
<OTHER_REFERENCES MODIFIED="2009-08-11 15:39:21 +1200" MODIFIED_BY="jane clarke">
<ADDITIONAL_REFERENCES MODIFIED="2009-08-11 15:39:21 +1200" MODIFIED_BY="jane clarke">
<REFERENCE ID="REF-Adashi-1985" NAME="Adashi 1985" TYPE="JOURNAL_ARTICLE">
<AU>Adashi EY, Resnick CE, DErcole AJ, Svoboda ME, Van Wyke J</AU>
<TI>Insulin-like growth factors as intraovarian regulators of granulosa cell growth and function</TI>
<SO>Endocrinology Review</SO>
<YR>1985</YR>
<VL>6</VL>
<PG>400-20</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Blumenfeld-1996" NAME="Blumenfeld 1996" TYPE="JOURNAL_ARTICLE">
<AU>Blumenfeld Z, Amit T</AU>
<TI>The role of growth hormone (GH), GH-receptor and GH-binding protein in reproduction and ovulation induction</TI>
<SO>Journal of Pediatric Endocrinology &amp; Metabolism</SO>
<YR>1996</YR>
<VL>9</VL>
<PG>145-62</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Cahill-2002" NAME="Cahill 2002" TYPE="JOURNAL_ARTICLE">
<AU>Cahill D, Wardle PG</AU>
<TI>Management of Infertility</TI>
<SO>BMJ: British Medical Journal</SO>
<YR>2002</YR>
<VL>325</VL>
<NO>7354</NO>
<PG>28-32</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Erickson-1989" NAME="Erickson 1989" TYPE="JOURNAL_ARTICLE">
<AU>Erickson GF, Gabriel VG, Magoffin DA</AU>
<TI>Insulin-like factor-I regulates aromataze activity in human granulosa and granulosa luteal cells</TI>
<SO>Journal of Clinical Endocrinological Metabolism</SO>
<YR>1989</YR>
<VL>69</VL>
<PG>716-24</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Higgins-2008" MODIFIED="2009-08-11 12:53:21 +1200" MODIFIED_BY="Julie A Brown" NAME="Higgins 2008" TYPE="BOOK">
<AU>Higgins</AU>
<TI>Cochrane Handbook for Systematic Reviews of Interventions</TI>
<SO>Cochrane Collaboration</SO>
<YR>2008</YR>
<PB>Wiley</PB>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Homburg-1988" MODIFIED="2009-08-11 15:39:21 +1200" MODIFIED_BY="jane clarke" NAME="Homburg 1988" TYPE="JOURNAL_ARTICLE">
<AU>Homburg R, Eshel A, Abdulla HI, Jacobs HS</AU>
<TI>Growth hormone facilitates ovulation induction by gonadotrophins</TI>
<SO>Clinical Endocrinology</SO>
<YR>1988</YR>
<VL>29</VL>
<PG>113-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Hsu-1987" NAME="Hsu 1987" TYPE="JOURNAL_ARTICLE">
<AU>Hsu DJ, Hammond JM</AU>
<TI>Concomitant effects of growth hormone on secretion of insulin-like growth factor I and progesterone by cultured porcine granulosa cells</TI>
<SO>Endocrinology</SO>
<YR>1987</YR>
<VL>121</VL>
<NO>4</NO>
<PG>1343-8</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Kyrou-2009" MODIFIED="2009-08-03 05:18:25 +1200" MODIFIED_BY="James M N Duffy" NAME="Kyrou 2009" TYPE="JOURNAL_ARTICLE">
<AU>Kyrou D, Kolibianakis EM, Venetis CA, Papanikolaou EG, Bontis J, Tarlatzis BC</AU>
<TI>How to improve the probability of pregnancy in poor responders undergoing in vitro fertilization: a systematic review and meta-analysis</TI>
<SO>Fertility and Sterility</SO>
<YR>2009</YR>
<VL>91</VL>
<NO>3</NO>
<PG>749-766</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Li-2005" MODIFIED="2009-07-20 07:39:04 +1200" MODIFIED_BY="James M N Duffy" NAME="Li 2005" TYPE="JOURNAL_ARTICLE">
<AU>Li P, Mah D, Lim K, Sprague S, Bhandari M</AU>
<TI>Randomization and concealment in surgical trials: a comparison between orthopaedic and non-orthopaedic randomized trials</TI>
<SO>Archives of Orthopeadic and Trauma Surgery</SO>
<YR>2005</YR>
<VL>125</VL>
<NO>1</NO>
<PG>1434-3916</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Mason-1990" NAME="Mason 1990" TYPE="JOURNAL_ARTICLE">
<AU>Mason HD, Martikainen H, Beard RW, Anyaoku V, Franks S</AU>
<TI>Direct gonadotrophic effect of growth hormone on oestradiol production by human granulosa cell in vitro</TI>
<SO>Journal of Endocrinology</SO>
<YR>1990</YR>
<VL>126</VL>
<PG>R1-R2</PG>
<IDENTIFIERS/>
</REFERENCE>
<REFERENCE ID="REF-Yoshimura-1996" NAME="Yoshimura 1996" TYPE="JOURNAL_ARTICLE">
<AU>Yoshimura Y, Ando M, Nagamatsu S, Iwashita M, Adachi T, Sueoka K</AU>
<TI>Effects of insulin-like growth factor-I on follicle growth, oocyte maturation, and ovarian steroidogenesis and plasminogen activator activity in the rabbit</TI>
<SO>Biology of Reproduction</SO>
<YR>1996</YR>
<VL>55</VL>
<NO>1</NO>
<PG>152-60</PG>
<IDENTIFIERS/>
</REFERENCE>
</ADDITIONAL_REFERENCES>
<OTHER_VERSIONS_REFERENCES/>
<PENDING_REFERENCES/>
</OTHER_REFERENCES>
</STUDIES_AND_REFERENCES>
<CHARACTERISTICS_OF_STUDIES MODIFIED="2009-08-11 15:45:14 +1200" MODIFIED_BY="jane clarke">
<CHARACTERISTICS_OF_INCLUDED_STUDIES MODIFIED="2009-08-11 15:45:14 +1200" MODIFIED_BY="jane clarke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<INCLUDED_CHAR MODIFIED="2009-08-11 15:35:54 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Bergh-1994">
<CHAR_METHODS MODIFIED="2009-08-11 15:35:54 +1200" MODIFIED_BY="jane clarke">
<P>Randomisation: Using a computerised list women were randomised to one of four arms.</P>
<P>Allocation Concealment: unclear.</P>
<P>Blinding: double-blind.</P>
<P>Trial Design: Parallel.</P>
<P>Analysis: power calculation was performed, no intention to treat analysis performed.</P>
<P>Study Setting: Multicentre study - three IVF programs in Sweden.</P>
<P>Withdrawals: two women (&lt; 10%).</P>
<P>Cancelled cycles: one woman in placebo group (&lt;10%).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 15:25:03 +1200" MODIFIED_BY="jane clarke">
<P>Number of women: 18 (nine growth hormone, nine placebo). IVF previous poor responders: at least two failed cycles with &lt; five oocytes. Regular menstrual cycle, normal FSH, LH, PRL and ovarian ultrasound. BMI less than or equal to 28, age 25 to 38 years. Normal semen quality, (WHO criteria).</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 15:24:56 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: growth hormone 0.1 IU/kg daily subcutaneous.</P>
<P>Treatment Protocol: seven days pretreatment with placebo; pre-treatment was started after ovarian down regulation was established (achieved with BA beginning on day one or two of cycle administered intranasally six/day or in a few cases by s/c injection two per day for a total dose of 1.2mg/day. Treatment with BA continued during the pre-treatment and stimulation periods). Ovarian stimulation was performed by hMG 225 to 300 IU/day IM and/or FSH in a dose of 75 to 300 IU/day for 10 to 25 days. Protocol, n=10 women and cycles. Dose of human chorionic gonadotropin: 10000 IU when at least one follicle was &gt;18mm diameter and there had been seven to eight days of continued rise of serum E2.<BR/>
</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 13:32:22 +1200" MODIFIED_BY="Julie A Brown">
<P>Pregnancy rate, oocyte retrieval and embryo transfer.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 15:24:46 +1200" MODIFIED_BY="jane clarke">
<P>This trial involved four treatment arms (and 40 women) but only data comparing growth hormone use in conjunction with GnRHa / hMG vs standard treatment (groups I, II) were included. Groups III and IV involved growth hormone pretreatment and were excluded. The placebo used was NaCl.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 15:34:06 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Dor-1995">
<CHAR_METHODS MODIFIED="2009-08-11 13:32:58 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomisation: stated as randomised. </P>
<P>Allocation concealment: sealed opaque sequentially numbered, identical envelopes. </P>
<P>Blinding: double-blind. </P>
<P>Trial Design: Parallel. </P>
<P>Analysis: No power calculation or intention to treat analysis performed.</P>
<P> Study setting: single centre, location Israel</P>
<P>
<BR/>Withdrawals: none (&lt;10%). Cancelled cycles: &lt;10%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 15:34:06 +1200" MODIFIED_BY="jane clarke">
<P>Number of women: 14 (seven growth hormone, seven placebo).</P>
<P>Inclusion Criteria: IVF previous poor responders defined as E2 &lt; 500 pg/ml on day of human chorionic gonadotropin, &lt; three oocytes retrieved. Normal serum FSH, LH levels. Cause of Subfertility: ovulatory disorders or tubal factor infertility. Age: 30 to 45.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 15:25:55 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: growth hormone 18 IU SC on days two, four, six, and eight of stimulation. Treatment Protocol: Short GnRHa/FSH/hMG protocol used, SC on cycle days two, four, six, and eight. Dose of human chorionic gonadotropin: 10000 IU when serum oestradiol was &gt;200pg/ml and at least two follicles were &gt; 18mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:06:50 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 10:06:56 +1200" MODIFIED_BY="jane clarke">
<P>Mannitol chosen as placebo because "no known ovarian effects."</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 15:34:42 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Hazout-2003">
<CHAR_METHODS MODIFIED="2009-08-11 13:34:08 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomisation: stated as randomised. </P>
<P>Allocation concealment: unclear. </P>
<P>Blinding: double. </P>
<P>Intention to treat analysis: not performed. </P>
<P>Power calculation: not performed. </P>
<P>Study setting: single centre - Paris, France. </P>
<P>Withdrawals: none. Cancelled cycles: &lt;10%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 13:35:02 +1200" MODIFIED_BY="Julie A Brown">
<P>Number of women n = 35 (12 growth hormone 4IU, 11 growth hormone 8IU, 12 placebo). </P>
<P>Inclusion criteria: women were &lt;39 years old with normal hormonal status and history of oocyte dysmorphia defined by &lt;50% of abnormal oocyte at previous attempts.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 15:34:26 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: four or eight IU sub cutaneous. Induction protocol: unclear. Dose of human chorionic gonadotropin: 1000 IU IM when at least two follicles were &gt;16mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:08:43 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 15:34:42 +1200" MODIFIED_BY="jane clarke">
<P>Thirty-five women in total were included in <LINK REF="STD-Hazout-2003" TYPE="STUDY">Hazout 2003</LINK> and they were divided into three groups, placebo, growth hormone four IU and growth hormone eight IU. Since only two groups could be compared for the table of comparisons the two growth hormone groups were separated and compared with half the placebo data for the meta-analysis but throughout the text the trial is referred to singly as <LINK REF="STD-Hazout-2003" TYPE="STUDY">Hazout 2003</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 15:35:03 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Hazout-2003-4-IU">
<CHAR_METHODS MODIFIED="2009-08-11 13:35:47 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomisation: stated as randomised. </P>
<P>Allocation concealment: unclear. </P>
<P>Blinding: double. </P>
<P>Intention to treat analysis: not performed. </P>
<P>Power calculation: not performed. </P>
<P>Study setting: single centre - Paris, France. </P>
<P>Withdrawals: none. Cancelled cycles: &lt;10%</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 15:34:50 +1200" MODIFIED_BY="jane clarke">
<P>Number of women n = 35 (12 growth hormone four IU, 11 growth hormone 8IU, 12 placebo).</P>
<P>Inclusion criteria: Women were &lt;39 years old with normal hormonal status and history of oocyte dysmorphia defined by &lt;50% of abnormal oocyte at previous attempts.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 15:33:16 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: four or eight IU sub cutaneous. Induction protocol: unclear. Dose of human chorionic gonadotropin: 1000 IU IM when at least two follicles were &gt;16mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:10:07 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 15:35:03 +1200" MODIFIED_BY="jane clarke">
<P>Same trial as <LINK REF="STD-Hazout-2003" TYPE="STUDY">Hazout 2003</LINK> but refers to women randomised to growth hormone four IU treatment arm.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 15:37:00 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Hazout-2003-8-IU">
<CHAR_METHODS MODIFIED="2009-08-11 13:36:59 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomisation: stated as randomised. </P>
<P>Allocation concealment: unclear. </P>
<P>Blinding: double. </P>
<P>Intention to treat analysis: not performed. </P>
<P>Power calculation: not performed. </P>
<P>Study setting: single centre - Paris, France. </P>
<P>Withdrawals: none. Cancelled cycles: &lt;10%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 15:36:50 +1200" MODIFIED_BY="jane clarke">
<P>Number of women n = 35 (12 growth hormone four IU, 11 growth hormone eight IU, 12 placebo).</P>
<P>Inclusion criteria: women were &lt;39 years old with normal hormonal status and history of oocyte dysmorphia defined by &lt;50% of abnormal oocyte at previous attempts.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 15:37:00 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: four or eight IU sub cutaneous. Induction protocol: unclear. Dose of human chorionic gonadotropin: 1000 IU IM when at least two follicles were &gt;16mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:11:32 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 13:37:36 +1200" MODIFIED_BY="Julie A Brown">
<P>Same trial as <LINK REF="STD-Hazout-2003" TYPE="STUDY">Hazout 2003</LINK>. but refers to women randomised to growth hormone 8 IU treatment arm.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 13:38:28 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Kueuk-2008">
<CHAR_METHODS MODIFIED="2009-08-11 10:12:23 +1200" MODIFIED_BY="jane clarke">
<P>Randomisation: computer generated randomisation. Allocation concealment: sealed envelopes. Blinding: triple. Intention to treat analysis: not performed. Power calculation: not performed. Study setting: single centre - Bursa, Turkey. Withdrawals: none. Cancelled cycles: &lt;10%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 13:38:28 +1200" MODIFIED_BY="Julie A Brown">
<P>Number of women n= 61 (31 growth hormone, 30 placebo).</P>
<P>Inclusion criteria: women who responded poorly to high dose gonadotrophin treatment in their first cycles in the same centre. Cause of subfertility: Not stated.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 10:12:48 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: growth hormone 12IU sub cutaneous from day 21 of preceding cycle along with GnRHa, until the day of human chorionic gonadotropin. Treatment Protocol: Long GnRHa/FSH/hMG protocol used. Dose of human chorionic gonadotropin: 10000 IU when sat least 1 follicle was &gt; 17mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:12:46 +1200" MODIFIED_BY="jane clarke">
<P>Clinical pregnancy.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 09:47:52 +1200" MODIFIED_BY="jane clarke"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 15:37:28 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Owen-1991">
<CHAR_METHODS MODIFIED="2009-08-11 13:38:40 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomisation: Two randomisation lists were made with 20 women on each list and block randomised into blocks of four. Allocation Concealment: method unclear Blinding: double-blind<BR/>Trial design: Parallel. Analysis: No power calculation or intention to treat analysis performed. Study setting: single centre, location London. Withdrawals: none (&lt;10%). Cancelled Cycles: &lt;10%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 15:37:28 +1200" MODIFIED_BY="jane clarke">
<P>Number of women:n= 25 (13 growth hormone, 12 placebo).</P>
<P>Inclusion criteria: one or more previous IVF cycles with poor response, defined as fewer than six oocytes retrieved from which fewer than three embryos developed.<BR/>Cause of subfertility: 18 of 25 women found to have polycystic ovaries on ultrasound. Age: &lt;38</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 10:13:48 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: growth hormone 24 IU intramuscular (IM), days 1, 3, 5, 7, 9, and 11 of hMG treatment, during long GnRHa protocol, vs placebo given IM on same cycle days as active treatment groups. Dose of human chorionic gonadotropin: 5000 IU</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:13:55 +1200" MODIFIED_BY="jane clarke">
<P>Live birth rate, pregnancy rate, adverse effects (multiple pregnancy and ectopic pregnancy).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 13:39:47 +1200" MODIFIED_BY="Julie A Brown">
<P>Nature of placebo not described. Follicular fluid IG1 increased by 27% with growth hormone treatment. The data from <LINK REF="STD-Jacobs-1995" TYPE="STUDY">Jacobs 1995</LINK> is also presented in <LINK REF="STD-Owen-1991" TYPE="STUDY">Owen 1991</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 15:45:14 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Suikkari-1996">
<CHAR_METHODS MODIFIED="2009-08-11 15:45:14 +1200" MODIFIED_BY="jane clarke">
<P>Randomisation: Stated as randomised.</P>
<P>Allocation Concealment: unclear.</P>
<P>Blinding: Double blind.</P>
<P>Trial Design: Parallel.</P>
<P>Analysis: No power calculation and no intention to treat analysis performed<BR/>Study Setting: two centres.</P>
<P>Analysis: No power calculation or intention-to-treat analysis performed.</P>
<P>Withdrawals: Withdrawals: &lt; 10% . Cancelled Cycles: &gt;10% (therefore include in meta-analysis but perform sensitivity analysis).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 15:44:44 +1200" MODIFIED_BY="jane clarke">
<P>Number of women: n= 22 (10 growth hormone 4 IU, 6 growth hormone 12 IU, 6 placebo)</P>
<P>Inclusion Criteria: previous poor response in more than or equal to two assisted cycles. Definition of poor Response: &lt; or equal to two oocytes retrieved or &gt; or equal to 48 AMP hMG consumed in a stimulation cycle. Cause of subfertility: tubal (n=10), endometriosis (n=1), male factor (n=2), idiopathic (n=9). Age 25-40 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 15:44:59 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: six women received 12 IU growth hormone and 10 women received four IU growth hormone daily SC from day three of spontaneous menstrual cycle. Study Protocol: A boost "flare-up" protocol was used for ovarian stimulation. On day two of spontaneous menstrual cycle leuprolide acetate was administered SC 0.75mg in the morning. On day three gonadotrophin Metrodin was started at 300IU SC for four days then adjusted according to serum E2 and follicular growth. Dose of human chorionic gonadotropin 5000 IU IM given when the largest follicle(s) reached a diameter of 18 to 20mm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:15:21 +1200" MODIFIED_BY="jane clarke">
<P>Live birth rate, pregnancy rate, embryo transfer and adverse effects (multiple pregnancy).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 15:44:07 +1200" MODIFIED_BY="jane clarke">
<P>Twenty two women in total were included in <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK> and they were divided into three groups, placebo, growth hormone four IU and growth hormone 12IU. Since only two groups could be compared for the table of comparisons the two growth hormone groups were separated and compared with half the placebo data for the meta-analysis but throughout the text the trial is referred to singly as <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK>.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 15:43:54 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Suikkari-1996-12-IU">
<CHAR_METHODS MODIFIED="2009-08-11 15:43:32 +1200" MODIFIED_BY="jane clarke">
<P>Randomisation: Stated as randomised.</P>
<P>Allocation concealment: unclear.</P>
<P>Blinding: Double blind.</P>
<P>Trial Design: Parallel.</P>
<P>Analysis: No power calculation and no intention to treat analysis performed</P>
<P>Study Setting: two centres.</P>
<P>Analysis: No power calculation or intention to treat analysis performed.</P>
<P>Withdrawals: Withdrawals: &lt; 10% . Cancelled Cycles: &gt;10% (therefore include in meta-analysis but perform sensitivity analysis).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 15:43:48 +1200" MODIFIED_BY="jane clarke">
<P>Number of women : n=22 (10 growth hormone four IU, six growth hormone 12 IU, six placebo) Inclusion Criteria: previous poor response in more than or equal to two assisted cycles. Definition of poor Response: &lt; or equal to two oocytes retrieved or &gt; or equal to 48 AMP hMG consumed in a stimulation cycle. Cause of subfertility: tubal (n=10), endometriosis (n=1), male factor (n=2), idiopathic (n=9). Age 25-40 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 15:43:54 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: six women received 12 IU growth hormone and 10 women received 4 IU growth hormone daily SC from day three of spontaneous menstrual cycle. Study Protocol: A boost "flare-up" protocol was used for ovarian stimulation. On day two of spontaneous menstrual cycle leuprolide acetate was administered SC 0.75mg in the morning. On day three gonadotrophin Metrodin was started at 300IU SC for four days then adjusted according to serum E2 and follicular growth. Dose of human chorionic gonadotropin 5000 IU IM given when the largest follicle(s) reached a diameter of 18 to 20mm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:16:54 +1200" MODIFIED_BY="jane clarke">
<P>Live birth rate, pregnancy rate, embryo transfer and adverse effects (multiple pregnancy).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 14:22:55 +1200" MODIFIED_BY="Julie A Brown">
<P>Same trial as <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK> but refers to women randomised to growth hormone 12 IU treatment arm.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 14:23:04 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Suikkari-1996-4-IU">
<CHAR_METHODS MODIFIED="2009-08-11 13:42:39 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomisation: Stated as randomised. </P>
<P>Allocation concealment: unclear. </P>
<P>Blinding: Double blind.</P>
<P>Trial Design: Parallel. </P>
<P>Analysis: No power calculation and no intention to treat analysis performed</P>
<P>Study Setting: 2 centres. </P>
<P>Analysis: No power calculation or intention to treat analysis performed.</P>
<P>Withdrawals: Withdrawals: &lt; 10% . Cancelled Cycles: &gt;10% (therefore include in meta-analysis but perform sensitivity analysis).</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 13:42:52 +1200" MODIFIED_BY="Julie A Brown">
<P>Number of women: 22 (10 growth hormone 4 IU, 6 growth hormone 12 IU, 6 placebo)</P>
<P>Inclusion Criteria: previous poor response in more than or equal to 2 assisted cycles. Definition of poor Response: &lt; or equal to 2 oocytes retrieved or &gt; or equal to 48 AMP hMG consumed in a stimulation cycle. Cause of subfertility: tubal (n=10), endometriosis (n=1), male factor (n=2), idiopathic (n=9). Age 25-40 years.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 14:23:00 +1200" MODIFIED_BY="Julie A Brown">
<P>Intervention: 6 women received 12 IU growth hormone and 10 women received 4 IU growth hormone daily SC from day 3 of spontaneous menstrual cycle. Study Protocol: A boost "flare-up" protocol was used for ovarian stimulation. On day 2 of spontaneous menstrual cycle leuprolide acetate was administered SC 0.75mg in the morning. On day 3 gonadotrophin Metrodin was started at 300IU SC for 4 days then adjusted according to serum E2 and follicular growth. Dose of human chorionic gonadotropin 5000 IU IM given when the largest follicle(s) reached a diameter of 18-20mm.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:18:12 +1200" MODIFIED_BY="jane clarke">
<P>Live birth rate, pregnancy rate, embryo transfer and adverse effects (multiple pregnancy).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 14:23:04 +1200" MODIFIED_BY="Julie A Brown">
<P>Same trial as <LINK REF="STD-Suikkari-1996" TYPE="STUDY">Suikkari 1996</LINK> but refers to women randomised to growth hormone 4 IU treatment arm.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 14:23:13 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Tapanainen-1992">
<CHAR_METHODS MODIFIED="2009-08-11 13:44:25 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomisation: Stated as randomised, method unclear. </P>
<P>Allocation concealment: trial codes kept in sealed envelopes until the study was completed. </P>
<P>Blinding: double-blind </P>
<P>Trial design: Parallel. </P>
<P>Analysis: Power calculation not done, no intention to treat analysis but no withdrawals. </P>
<P>Study Setting: single centre. Finland</P>
<P>Withdrawals: none (&lt;10%). Cancelled cycles: &lt;10%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 14:23:07 +1200" MODIFIED_BY="Julie A Brown">
<P>Number of women randomised: n=38 (19 growth hormone, 19 placebo). Cause of Subfertility: normally cycling women with unexplained infertility, tubal infertility or mild to moderate endometriosis. Age: 27-37. </P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 10:20:03 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: growth hormone 24 IU IM beginning on cycle day four, then every 2 days until human chorionic gonadotropin, vs sterile saline IM on same cycle days. Treatment Protocol: Short GnRHa protocol used for ovulation induction, 300µg BA 3 times daily on cycle days 1-4. Three ampoules of hMG given IM on day 4 and then 150-223 IU daily until human chorionic gonadotropin injection. 5000 IU human chorionic gonadotropin given. Clinical Pregnancy Diagnosis: USS at six weeks gestation</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:20:14 +1200" MODIFIED_BY="jane clarke">
<P>Live birth rate and adverse effects (multiple pregnancies)</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 14:23:13 +1200" MODIFIED_BY="Julie A Brown">
<P>There were two parts to this trial, A and B. Only data from part A was included as part B studied the effect of growth hormone on gene expression of steroidogenic enzymes in granulosa cells and the women were not followed up for live birth or pregnancy data.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 13:45:57 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Tesarik-2005">
<CHAR_METHODS MODIFIED="2009-08-11 13:44:57 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomisation: truly randomised, computer generated random number tables. </P>
<P>Allocation concealment: clear, opaque envelopes. </P>
<P>Blinding: double-blinded. </P>
<P>Analysis: Power calculation performed and intention to treat analysis not performed. </P>
<P>Study setting: multi-centre, Spain and France. </P>
<P>Withdrawals: none. Cancelled cycles: &lt;10%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 13:45:37 +1200" MODIFIED_BY="Julie A Brown">
<P>Number of women: 100 (50, growth hormone, 50 placebo). Inclusion criteria: women &gt;40 years old asking for an assisted reproduction attempt by ICSI were assessed for eligibility.</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 13:45:57 +1200" MODIFIED_BY="Julie A Brown">
<P>Intevention: growth hormone 8IU Subcut. Treatment Protocol: Long. Dose of human chorionic gonadotropin: 25mg when at least 1 follicle measured &gt;18mm in diameter.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:22:02 +1200" MODIFIED_BY="jane clarke">
<P>Live birth rate, pregnancy rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 09:49:26 +1200" MODIFIED_BY="jane clarke"/>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 14:23:17 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Younis-1992">
<CHAR_METHODS MODIFIED="2009-08-11 13:46:28 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomisation: Prospectively randomised, method unclear. </P>
<P>Allocation concealment: allocation not revealed until all outcome measures were calculated and comparison between the two groups had been performed. </P>
<P>Blinding: double-blind. </P>
<P>Study design: placebo controlled trial. </P>
<P>Sensitivity analysis: No power calculation or intention to treat analysis performed. </P>
<P>Study setting: single centre, location Israel. </P>
<P>Withdrawals: none (&lt; 10%). Cancelled Cycles: &lt;10%.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 14:23:17 +1200" MODIFIED_BY="Julie A Brown">
<P>Number of women randomised: n= 42 (20 growth hormone, 22 placebo). Cause of Subfertility: Ovulating women with mechanical factor infertility. Normal serum FSH, LH, PRL, T and DHEAS. Normal semen (WHO criteria).<BR/>Exclusion Criteria: ? Age: &lt; or equal to 38 years</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 13:47:19 +1200" MODIFIED_BY="Julie A Brown">
<P>Intervention: growth hormone 12 IU SC on days 1, 3, 5, and 7 of hMG treatment vs Mannitol 30 mg SC on same cycle days. Treatment Protocol: All women received GnRHa/hMG 0.5mg/day from day 21 of previous cycle ovulation induction protocol.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:23:09 +1200" MODIFIED_BY="jane clarke">
<P>Pregnancy rate, oocyte retrieval, embryo transfer, ampoules of Gonadotrophin used and adverse effects (multiple pregnancy).</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 10:23:14 +1200" MODIFIED_BY="jane clarke">
<P>Mannitol chosen as placebo.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<INCLUDED_CHAR MODIFIED="2009-08-11 13:48:38 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Zhuang-1994">
<CHAR_METHODS MODIFIED="2009-08-11 13:47:45 +1200" MODIFIED_BY="Julie A Brown">
<P>Randomisation: stated as randomised, method unclear. </P>
<P>Allocation concealment: unclear of method</P>
<P>Blinding: Outcome assessors were blind to treatment allocation. </P>
<P>Study Design: Parallel. </P>
<P>Study Setting: unclear. </P>
<P>Analysis; Power calculation done. </P>
<P>Withdrawals; none. Cancelled Cycles; none.</P>
</CHAR_METHODS>
<CHAR_PARTICIPANTS MODIFIED="2009-08-11 13:48:38 +1200" MODIFIED_BY="Julie A Brown">
<P>Number of women randomised: n=27 (12 growth hormone, 15 control). Definition of poor response: not provided</P>
<P>Inclusion Criteria: previous sub-optimal response to hyperstimulation cycles in IVF. Exclusion Criteria: Cause of subfertility: tubal factor or unexplained. Age: growth hormone 33.2 +/-3.9, Placebo 32.3 +/-3.9.<BR/>
</P>
</CHAR_PARTICIPANTS>
<CHAR_INTERVENTIONS MODIFIED="2009-08-11 10:24:24 +1200" MODIFIED_BY="jane clarke">
<P>Intervention: growth hormone 12 IU IM on alternate days. Treatment Protocol: GnRH-a (Buserelin nasal spray) from day 21 of previous menstrual cycle to day of human chorionic gonadotropin injection (do not know dose of GnRH-a)<BR/>2 IU hMG given on alternate days for 12 days (at same time as growth hormone). Dose of human chorionic gonadotropin: 10000 iu.</P>
</CHAR_INTERVENTIONS>
<CHAR_OUTCOMES MODIFIED="2009-08-11 10:24:32 +1200" MODIFIED_BY="jane clarke">
<P>Live birth rate and pregnancy rate.</P>
</CHAR_OUTCOMES>
<CHAR_NOTES MODIFIED="2009-08-11 10:24:38 +1200" MODIFIED_BY="jane clarke">
<P>Some information will have been stated in the trial but was not translated. The sections that were translated were kindly done so by Teresa Gu.</P>
</CHAR_NOTES>
</INCLUDED_CHAR>
<FOOTNOTES>
<P>BA: Buserelin Acetate<BR/>E2: Oestrogen<BR/>Only outcomes relevant to the review were stated in the table of included studies<BR/>GnRH-a: Gonadotrophin releasing hormone agonist</P>
</FOOTNOTES>
</CHARACTERISTICS_OF_INCLUDED_STUDIES>
<CHARACTERISTICS_OF_EXCLUDED_STUDIES MODIFIED="2009-08-11 14:23:29 +1200" MODIFIED_BY="Julie A Brown" SORT_BY="STUDY">
<EXCLUDED_CHAR MODIFIED="2009-08-11 14:23:22 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Blumenfeld-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 14:23:22 +1200" MODIFIED_BY="Julie A Brown">
<P>During the 2009 update additional data was sort to clarify which women included in the trial received which method of assisted conception and the definition of poor responder used.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 10:26:07 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Busacca-1996">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 10:26:07 +1200" MODIFIED_BY="jane clarke">
<P>Method of assisted conception used was not IVF but artificial insemination-husband or GIFT.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 10:26:17 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Homburg-1990">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 10:26:17 +1200" MODIFIED_BY="jane clarke">
<P>Not stated as randomised, no useful outcomes reported.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 13:50:24 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Homburg-1990b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 13:50:24 +1200" MODIFIED_BY="Julie A Brown">
<P>Women did not undergo IVF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 13:50:37 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Homburg-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 13:50:37 +1200" MODIFIED_BY="Julie A Brown">
<P>Women did not undergo IVF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 13:50:49 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Howles-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 13:50:49 +1200" MODIFIED_BY="Julie A Brown">
<P>Intervention is growth hormone releasing factor not growth hormone.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 13:51:04 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Hughes-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 13:51:04 +1200" MODIFIED_BY="Julie A Brown">
<P>Any women who failed to produce 3 follicles greater than 20mm were cancelled. These women were not included in the analysis. This unpublished information could not be obtained from the author.</P>
<P>Hughes 1992 and Huang 1993 are the same trial as <LINK REF="STD-Hughes-1994" TYPE="STUDY">Hughes 1994</LINK>.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 10:26:55 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Jacobs-1995">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 10:26:55 +1200" MODIFIED_BY="jane clarke">
<P>Only concerns ovulation induction, not IVF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 10:26:57 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Landolfi-1994">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 10:26:57 +1200" MODIFIED_BY="jane clarke">
<P>Only concerns ovulation induction, not IVF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 14:23:29 +1200" MODIFIED_BY="Julie A Brown" STUDY_ID="STD-Owen-1991b">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 14:23:29 +1200" MODIFIED_BY="Julie A Brown">
<P>There are two publications for this trial. The analysis used women randomised to receive growth hormone in the trial and retrospective cases of women who had also received growth hormone in the past.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 10:27:13 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Rinehart-1999">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 10:27:13 +1200" MODIFIED_BY="jane clarke">
<P>Allocation was stated as "alternating randomisation", suggesting allocation to groups by alternation, not randomisation.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 10:27:23 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Schoolcraft-1997">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 10:27:23 +1200" MODIFIED_BY="jane clarke">
<P>Both treatment groups received the same dose of growth hormone, the intervention was oral contraceptive.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<EXCLUDED_CHAR MODIFIED="2009-08-11 10:27:32 +1200" MODIFIED_BY="jane clarke" STUDY_ID="STD-Tulandi-1993">
<CHAR_REASON_FOR_EXCLUSION MODIFIED="2009-08-11 10:27:32 +1200" MODIFIED_BY="jane clarke">
<P>Method of assisted conception was intra uterine insemination not IVF.</P>
</CHAR_REASON_FOR_EXCLUSION>
</EXCLUDED_CHAR>
<FOOTNOTES/>
</CHARACTERISTICS_OF_EXCLUDED_STUDIES>
<CHARACTERISTICS_OF_AWAITING_STUDIES MODIFIED="2009-08-11 11:45:14 +1200" MODIFIED_BY="jane clarke" SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_AWAITING_STUDIES>
<CHARACTERISTICS_OF_ONGOING_STUDIES SORT_BY="STUDY" USER_DEF_1_ENABLED="NO" USER_DEF_2_ENABLED="NO" USER_DEF_3_ENABLED="NO">
<FOOTNOTES/>
</CHARACTERISTICS_OF_ONGOING_STUDIES>
</CHARACTERISTICS_OF_STUDIES>
<QUALITY_ITEMS MODIFIED="2009-08-11 15:39:00 +1200" MODIFIED_BY="jane clarke">
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-01" LEVEL="STUDY" MODIFIED="2009-08-11 15:38:55 +1200" MODIFIED_BY="jane clarke" NO="1">
<NAME>Adequate sequence generation?</NAME>
<DESCRIPTION>
<P>Was the allocation sequence adequately generated?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:35:47 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Bergh-1994">
<DESCRIPTION>
<P>Randomisation: Using a computerised list women were randomised to one of four arms</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:07:17 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Dor-1995">
<DESCRIPTION>
<P>Stated as 'randomised' no other details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:09:02 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Hazout-2003">
<DESCRIPTION>
<P>Stated as randomised. No other details</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:35:20 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Hazout-2003-4-IU">
<DESCRIPTION>
<P>Stated as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:15 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Hazout-2003-8-IU">
<DESCRIPTION>
<P>Stated as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:20 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Kueuk-2008">
<DESCRIPTION>
<P>Computer generated randomisation</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:35 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Owen-1991">
<DESCRIPTION>
<P>Two randomisation lists were made with 20 women on each list and block randomised into blocks of four</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:47 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Suikkari-1996">
<DESCRIPTION>
<P>Stated as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:58 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Suikkari-1996-12-IU">
<DESCRIPTION>
<P>Stated as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:11 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Suikkari-1996-4-IU">
<DESCRIPTION>
<P>Stated as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:22 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Tapanainen-1992">
<DESCRIPTION>
<P>Stated as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:28 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Tesarik-2005">
<DESCRIPTION>
<P>Computer generated random number tables</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:44 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Younis-1992">
<DESCRIPTION>
<P>Stated as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:55 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Zhuang-1994">
<DESCRIPTION>
<P>Stated as randomised</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-02" LEVEL="STUDY" MODIFIED="2009-08-11 15:38:46 +1200" MODIFIED_BY="jane clarke" NO="2">
<NAME>Allocation concealment?</NAME>
<DESCRIPTION>
<P>Was allocation adequately concealed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:35:45 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Bergh-1994">
<DESCRIPTION>
<P>Not stated within the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:36:11 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Dor-1995">
<DESCRIPTION>
<P>Sealed opaque sequentially numbered, identical envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:35:29 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Hazout-2003">
<DESCRIPTION>
<P>Not stated within the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:35:19 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Hazout-2003-4-IU">
<DESCRIPTION>
<P>Not stated within the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:14 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Hazout-2003-8-IU">
<DESCRIPTION>
<P>Not stated within the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:13:02 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Kueuk-2008">
<DESCRIPTION>
<P>Sealed envelopes. No details as to whether opaque</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:34 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Owen-1991">
<DESCRIPTION>
<P>Not stated within the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:48 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Suikkari-1996">
<DESCRIPTION>
<P>Not stated within the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:59 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Suikkari-1996-12-IU">
<DESCRIPTION>
<P>Not stated within the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:12 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Suikkari-1996-4-IU">
<DESCRIPTION>
<P>Not stated within the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:20:52 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Tapanainen-1992">
<DESCRIPTION>
<P>Trial codes kept in sealed envelopes until the end of the study, no details as to whether centralised or envelopes opaque</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:30 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Tesarik-2005">
<DESCRIPTION>
<P>Opaque envelopes</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:46 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Younis-1992">
<DESCRIPTION>
<P>Allocation not revealed until all outcomes calculated and comparisons between groups performed</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:24:55 +1200" MODIFIED_BY="jane clarke" RESULT="UNKNOWN" STUDY_ID="STD-Zhuang-1994">
<DESCRIPTION>
<P>Not stated within the text</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-03" LEVEL="GROUP" MODIFIED="2009-08-11 15:38:57 +1200" MODIFIED_BY="jane clarke" NO="3">
<NAME>Blinding?</NAME>
<DESCRIPTION>
<P>Was knowledge of the allocated interventions adequately prevented during the study?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA_ENTRY_GROUP ID="QIG-03.01" NO="1">
<NAME>All outcomes</NAME>
</QUALITY_ITEM_DATA_ENTRY_GROUP>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:35:42 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Bergh-1994">
<DESCRIPTION>
<P>Double-blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:36:10 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Dor-1995">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:36:27 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Hazout-2003">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:35:17 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Hazout-2003-4-IU">
<DESCRIPTION>
<P>Doubleblinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:37:12 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Hazout-2003-8-IU">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 10:13:09 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Kueuk-2008">
<DESCRIPTION>
<P>Triple blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:37:39 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Owen-1991">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:37:53 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Suikkari-1996">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:38:05 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Suikkari-1996-12-IU">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:38:16 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Suikkari-1996-4-IU">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:38:25 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Tapanainen-1992">
<DESCRIPTION>
<P>Double blinding</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:38:35 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Tesarik-2005">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:38:47 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Younis-1992">
<DESCRIPTION>
<P>Double blinded</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY GROUP_ID="QIG-03.01" MODIFIED="2009-08-11 15:38:57 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Zhuang-1994">
<DESCRIPTION>
<P>Single</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-04" LEVEL="GROUP" NO="4">
<NAME>Incomplete outcome data addressed?</NAME>
<DESCRIPTION>
<P>Were incomplete outcome data adequately addressed?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA/>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-05" LEVEL="STUDY" MODIFIED="2009-08-11 15:39:00 +1200" MODIFIED_BY="jane clarke" NO="5">
<NAME>Free of selective reporting?</NAME>
<DESCRIPTION>
<P>Are reports of the study free of suggestion of selective outcome reporting?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:06:00 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Bergh-1994">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:36:12 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Dor-1995">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:35:35 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Hazout-2003">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:35:21 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Hazout-2003-4-IU">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:13 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Hazout-2003-8-IU">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:23 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Kueuk-2008">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:42 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Owen-1991">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:16:12 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Suikkari-1996">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:07 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Suikkari-1996-12-IU">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:19 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Suikkari-1996-4-IU">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:26 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Tapanainen-1992">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:38 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Tesarik-2005">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:23:59 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Younis-1992">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:39:00 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Zhuang-1994">
<DESCRIPTION>
<P>There is no indication the study has reported outcomes selectively</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
<QUALITY_ITEM CORE_ITEM="YES" ID="QIT-06" LEVEL="STUDY" MODIFIED="2009-08-11 15:38:39 +1200" MODIFIED_BY="jane clarke" NO="6">
<NAME>Free of other bias?</NAME>
<DESCRIPTION>
<P>Was the study apparently free of other problems that could put it at a high risk of bias?</P>
</DESCRIPTION>
<QUALITY_ITEM_DATA>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:06:13 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Bergh-1994">
<DESCRIPTION>
<P>The study does not report on adverse effects or multiple pregnancies</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:36:08 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Dor-1995">
<DESCRIPTION>
<P>No adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:35:36 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Hazout-2003">
<DESCRIPTION>
<P>No adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:35:23 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Hazout-2003-4-IU">
<DESCRIPTION>
<P>No adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:16 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Hazout-2003-8-IU">
<DESCRIPTION>
<P>No adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:13:23 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Kueuk-2008">
<DESCRIPTION>
<P>No adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:37:43 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Owen-1991">
<DESCRIPTION>
<P>Nature of placebo not described. Follicular fluid IG1 increased by 27% with growth hormone treatment</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:16:20 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Suikkari-1996">
<DESCRIPTION>
<P>Cancelled Cycles: &gt;10% (therefore include in meta-analysis but perform sensitivity analysis).</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:17:37 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Suikkari-1996-12-IU">
<DESCRIPTION>
<P>Cancelled Cycles: &gt;10% (therefore include in meta-analysis but perform sensitivity analysis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:19:31 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Suikkari-1996-4-IU">
<DESCRIPTION>
<P>Cancelled Cycles: &gt;10% (therefore include in meta-analysis but perform sensitivity analysis)</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:27 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Tapanainen-1992">
<DESCRIPTION>
<P>Report both live birth rate and adverse effects</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 15:38:39 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Tesarik-2005">
<DESCRIPTION>
<P>No details of adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 09:50:23 +1200" MODIFIED_BY="jane clarke" RESULT="YES" STUDY_ID="STD-Younis-1992">
<DESCRIPTION/>
</QUALITY_ITEM_DATA_ENTRY>
<QUALITY_ITEM_DATA_ENTRY MODIFIED="2009-08-11 10:25:13 +1200" MODIFIED_BY="jane clarke" RESULT="NO" STUDY_ID="STD-Zhuang-1994">
<DESCRIPTION>
<P>No details of adverse effects reported</P>
</DESCRIPTION>
</QUALITY_ITEM_DATA_ENTRY>
</QUALITY_ITEM_DATA>
</QUALITY_ITEM>
</QUALITY_ITEMS>
<SOF_TABLES/>
<ADDITIONAL_TABLES/>
<ANALYSES_AND_DATA CALCULATED_DATA="YES" MODIFIED="2009-08-11 15:41:06 +1200" MODIFIED_BY="jane clarke">
<COMPARISON ID="CMP-001" MODIFIED="2009-08-11 14:06:09 +1200" MODIFIED_BY="Julie A Brown" NO="1">
<NAME>Growth hormone versus placebo: Routine use</NAME>
<DICH_OUTCOME CHI2="0.9186345605451376" CI_END="4.4318829876315755" CI_START="0.3953143126406358" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.3236263736263734" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.01" LOG_CI_END="0.6465882854530512" LOG_CI_START="-0.4030574614265142" LOG_EFFECT_SIZE="0.1217654120132685" METHOD="MH" MODIFIED="2009-08-11 13:54:22 +1200" MODIFIED_BY="Julie A Brown" NO="1" P_CHI2="0.3378338867024462" P_Q="0.0" P_Z="0.6492992236565516" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="41" WEIGHT="100.0" Z="0.45473593889781194">
<NAME>Live birth rate per woman randomised</NAME>
<GROUP_LABEL_1>GH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<DICH_DATA CI_END="5.697284880557696" CI_START="0.03914036805873493" EFFECT_SIZE="0.4722222222222222" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="2" LOG_CI_END="0.7556679359672871" LOG_CI_START="-1.4073750947453136" LOG_EFFECT_SIZE="-0.3258535793890133" ORDER="25697" O_E="0.0" SE="1.2705821834762678" STUDY_ID="STD-Tapanainen-1992" TOTAL_1="19" TOTAL_2="19" VAR="1.6143790849673203" WEIGHT="41.53846153846154"/>
<DICH_DATA CI_END="8.18181073608828" CI_START="0.45459225042894086" EFFECT_SIZE="1.9285714285714286" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="4" LOG_CI_END="0.9128494290583254" LOG_CI_START="-0.3423779720968269" LOG_EFFECT_SIZE="0.2852357284807493" ORDER="25698" O_E="0.0" SE="0.737326788914382" STUDY_ID="STD-Younis-1992" TOTAL_1="20" TOTAL_2="22" VAR="0.5436507936507936" WEIGHT="58.46153846153846"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="6.499715881043865" CI_START="0.4862510738935428" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.7777777777777777" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" I2="0.0" I2_Q="0.0" ID="CMP-001.02" LOG_CI_END="0.8128943729518269" LOG_CI_START="-0.3131394265186271" LOG_EFFECT_SIZE="0.24987747321659987" METHOD="MH" MODIFIED="2009-08-11 13:54:33 +1200" MODIFIED_BY="Julie A Brown" NO="2" P_CHI2="1.0" P_Q="0.0" P_Z="0.38437210404638034" Q="0.0" RANDOM="NO" SCALE="100.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.8698688232675175">
<NAME>Pregnancy rate per woman randomised</NAME>
<GROUP_LABEL_1>GH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<DICH_DATA CI_END="6.499715881043865" CI_START="0.4862510738935428" EFFECT_SIZE="1.7777777777777777" ESTIMABLE="YES" EVENTS_1="8" EVENTS_2="6" LOG_CI_END="0.8128943729518269" LOG_CI_START="-0.3131394265186271" LOG_EFFECT_SIZE="0.24987747321659987" ORDER="25701" O_E="0.0" SE="0.6614378277661477" STUDY_ID="STD-Younis-1992" TOTAL_1="20" TOTAL_2="22" VAR="0.4375" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="74.3122791004773" CI_START="0.11010644244117765" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" I2="0.0" I2_Q="0.0" ID="CMP-001.03" LOG_CI_END="1.871060580987677" LOG_CI_START="-0.9581872692680543" LOG_EFFECT_SIZE="0.4564366558598114" METHOD="MH" MODIFIED="2009-08-11 13:58:22 +1200" MODIFIED_BY="Julie A Brown" NO="3" P_CHI2="1.0" P_Q="0.0" P_Z="0.5271295846577561" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="0.6323938050378103">
<NAME>Number of women with at least one oocyte retrieved per woman randomised</NAME>
<GROUP_LABEL_1>GH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<DICH_DATA CI_END="74.3122791004773" CI_START="0.11010644244117765" EFFECT_SIZE="2.86046511627907" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="21" LOG_CI_END="1.871060580987677" LOG_CI_START="-0.9581872692680543" LOG_EFFECT_SIZE="0.4564366558598114" ORDER="25703" O_E="0.0" SE="1.6619141922429452" STUDY_ID="STD-Younis-1992" TOTAL_1="20" TOTAL_2="22" VAR="2.7619587823785214" WEIGHT="100.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="151.90770219177256" CI_START="0.356496101479278" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="7.358974358974359" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" I2="0.0" I2_Q="0.0" ID="CMP-001.04" LOG_CI_END="2.181579794498616" LOG_CI_START="-0.4479452150836296" LOG_EFFECT_SIZE="0.866817289707493" METHOD="MH" MODIFIED="2009-08-11 13:58:57 +1200" MODIFIED_BY="Julie A Brown" NO="4" P_CHI2="1.0" P_Q="0.0" P_Z="0.1962893241541575" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="20" TOTAL_2="22" WEIGHT="100.0" Z="1.2921958626080678">
<NAME>Embryo transfer per woman randomised</NAME>
<GROUP_LABEL_1>GH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<DICH_DATA CI_END="151.90770219177256" CI_START="0.356496101479278" EFFECT_SIZE="7.358974358974359" ESTIMABLE="YES" EVENTS_1="20" EVENTS_2="19" LOG_CI_END="2.181579794498616" LOG_CI_START="-0.4479452150836296" LOG_EFFECT_SIZE="0.866817289707493" ORDER="25705" O_E="0.0" SE="1.5445960069873335" STUDY_ID="STD-Younis-1992" TOTAL_1="20" TOTAL_2="22" VAR="2.385776824801215" WEIGHT="100.0"/>
</DICH_OUTCOME>
<CONT_OUTCOME CHI2="0.5760393360449981" CI_END="1.866835190431192" CI_START="-1.5051017193302407" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="MD" EFFECT_SIZE="0.18086673555047558" ESTIMABLE="YES" I2="0.0" I2_Q="0.0" ID="CMP-001.05" MODIFIED="2009-08-11 13:58:22 +1200" MODIFIED_BY="Julie A Brown" NO="5" P_CHI2="0.4478691034196982" P_Q="1.0" P_Z="0.8334644935461082" Q="0.0" RANDOM="NO" SCALE="32.15931984902084" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="YES" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="41" UNITS="" WEIGHT="100.00000000000001" Z="0.21026033236508154">
<NAME>Mean number of ampoules of gonadotrophin used per woman</NAME>
<GROUP_LABEL_1>GH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<CONT_DATA CI_END="4.645866066009736" CI_START="-2.0458660660097343" EFFECT_SIZE="1.3000000000000007" ESTIMABLE="YES" MEAN_1="19.0" MEAN_2="17.7" MODIFIED="2009-06-15 09:43:20 +1200" MODIFIED_BY="James M N Duffy" ORDER="25707" SD_1="5.6" SD_2="4.9" SE="1.7071058919457192" STUDY_ID="STD-Tapanainen-1992" TOTAL_1="19" TOTAL_2="19" WEIGHT="25.39111570336517"/>
<CONT_DATA CI_END="1.7518847535921986" CI_START="-2.1518847535922045" EFFECT_SIZE="-0.20000000000000284" ESTIMABLE="YES" MEAN_1="37.4" MEAN_2="37.6" ORDER="25708" SD_1="3.7" SD_2="2.6" SE="0.9958778676488034" STUDY_ID="STD-Younis-1992" TOTAL_1="20" TOTAL_2="22" WEIGHT="74.60888429663484"/>
</CONT_OUTCOME>
<DICH_OUTCOME CHI2="0.20496227606893705" CI_END="2.1499911102487292" CI_START="0.18122521823865717" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.6242055816523902" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-001.06" LOG_CI_END="0.33243666420495227" LOG_CI_START="-0.7417813685806248" LOG_EFFECT_SIZE="-0.20467235218783633" METHOD="MH" MODIFIED="2009-08-11 14:06:09 +1200" MODIFIED_BY="Julie A Brown" NO="6" P_CHI2="0.6507449173406781" P_Q="0.0" P_Z="0.4551422358180569" Q="0.0" RANDOM="NO" SCALE="341.74" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="39" TOTAL_2="41" WEIGHT="100.0" Z="0.7468696794802921">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="8.26436758434319" CI_START="0.012101023352951256" EFFECT_SIZE="0.3162393162393162" ESTIMABLE="YES" EVENTS_1="0" EVENTS_2="1" LOG_CI_END="0.9172096255858116" LOG_CI_START="-1.9171779009441448" LOG_EFFECT_SIZE="-0.4999841376791667" MODIFIED="2008-10-02 05:55:03 +1300" MODIFIED_BY="James M N Duffy" ORDER="104" O_E="0.0" SE="1.6649332635282328" STUDY_ID="STD-Tapanainen-1992" TOTAL_1="19" TOTAL_2="19" VAR="2.7720027720027716" WEIGHT="22.630560928433265"/>
<DICH_DATA CI_END="2.7622108913749615" CI_START="0.18470859094277406" EFFECT_SIZE="0.7142857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="7" LOG_CI_END="0.4412568333533967" LOG_CI_START="-0.7335129047098727" LOG_EFFECT_SIZE="-0.146128035678238" MODIFIED="2008-10-02 05:55:18 +1300" MODIFIED_BY="James M N Duffy" ORDER="105" O_E="0.0" SE="0.6900655593423543" STUDY_ID="STD-Younis-1992" TOTAL_1="20" TOTAL_2="22" VAR="0.47619047619047616" WEIGHT="77.36943907156673"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-002" MODIFIED="2009-08-11 15:40:10 +1200" MODIFIED_BY="jane clarke" NO="2">
<NAME>Growth hormone versus placebo: Poor responder as defined by the study</NAME>
<DICH_OUTCOME CHI2="0.9379993594417225" CI_END="15.354086456493379" CI_START="1.8917239127781604" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="5.3894055802668825" ESTIMABLE="YES" EVENTS_1="21" EVENTS_2="4" I2="0.0" I2_Q="0.0" ID="CMP-002.01" LOG_CI_END="1.1862239817229776" LOG_CI_START="0.2768577536798527" LOG_EFFECT_SIZE="0.7315408677014151" METHOD="MH" MODIFIED="2009-08-11 13:59:14 +1200" MODIFIED_BY="Julie A Brown" NO="1" P_CHI2="0.8162493465325006" P_Q="0.0" P_Z="0.0016138534638863579" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="85" TOTAL_2="80" WEIGHT="100.0" Z="3.1533912513979123">
<NAME>Live birth rate per woman randomised</NAME>
<GROUP_LABEL_1>Growth Hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<DICH_DATA CI_END="21.997397390540314" CI_START="0.4801704407332415" EFFECT_SIZE="3.25" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="2" LOG_CI_END="1.3423713005590432" LOG_CI_START="-0.3186045786012944" LOG_EFFECT_SIZE="0.5118833609788743" MODIFIED="2009-07-18 23:53:25 +1200" MODIFIED_BY="James M N Duffy" ORDER="33" O_E="0.0" SE="0.9756654533819863" STUDY_ID="STD-Zhuang-1994" TOTAL_1="12" TOTAL_2="15" VAR="0.9519230769230769" WEIGHT="32.349373230893654"/>
<DICH_DATA CI_END="54.80326328921184" CI_START="0.07734492566419716" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7388064195482726" LOG_CI_START="-1.1115681736042693" LOG_EFFECT_SIZE="0.3136191229720017" MODIFIED="2008-10-02 07:38:44 +1300" MODIFIED_BY="James M N Duffy" ORDER="36" O_E="0.0" SE="1.6743241455995954" STUDY_ID="STD-Suikkari-1996-4-IU" TOTAL_1="10" TOTAL_2="3" VAR="2.803361344537815" WEIGHT="15.467044076021027"/>
<DICH_DATA CI_END="32.36734832531703" CI_START="1.4157009325122636" EFFECT_SIZE="6.769230769230769" ESTIMABLE="YES" EVENTS_1="11" EVENTS_2="2" LOG_CI_END="1.510107121557232" LOG_CI_START="0.1509715181294317" LOG_EFFECT_SIZE="0.8305393198433318" MODIFIED="2008-10-02 07:59:50 +1300" MODIFIED_BY="James M N Duffy" ORDER="60" O_E="0.0" SE="0.7983629812832318" STUDY_ID="STD-Tesarik-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.63738344988345" WEIGHT="42.579862515163775"/>
<DICH_DATA CI_END="247.83320377698894" CI_START="0.5658461212078016" EFFECT_SIZE="11.842105263157896" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.394159491108236" LOG_CI_START="-0.24730165679116894" LOG_EFFECT_SIZE="1.0734289171585336" MODIFIED="2009-07-18 10:16:37 +1200" MODIFIED_BY="James M N Duffy" ORDER="152" O_E="0.0" SE="1.5516073537196706" STUDY_ID="STD-Owen-1991" TOTAL_1="13" TOTAL_2="12" VAR="2.407485380116959" WEIGHT="9.603720177921554"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.7392462083846059" CI_END="6.1993632849807865" CI_START="1.7383463338880356" CI_STUDY="95" CI_TOTAL="95" DF="7.0" EFFECT_MEASURE="OR" EFFECT_SIZE="3.282779377126407" ESTIMABLE="YES" EVENTS_1="47" EVENTS_2="16" I2="0.0" I2_Q="0.0" ID="CMP-002.02" LOG_CI_END="0.7923470869145119" LOG_CI_START="0.24013630600917074" LOG_EFFECT_SIZE="0.5162416964618414" METHOD="MH" MODIFIED="2009-08-11 15:40:10 +1200" MODIFIED_BY="jane clarke" NO="2" P_CHI2="0.9728550669643227" P_Q="0.0" P_Z="2.477278264398344E-4" Q="0.0" RANDOM="NO" SCALE="156.34471434465257" SORT_BY="STUDY" STUDIES="8" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="148" TOTAL_2="131" WEIGHT="100.00000000000003" Z="3.6645975318490245">
<NAME>Pregnancy rate per woman randomised</NAME>
<GROUP_LABEL_1>GH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.223640757660439" CI_START="0.21531055600870871" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.1530107749157927" LOG_CI_START="-0.6669346775432038" LOG_EFFECT_SIZE="0.24303804868629442" MODIFIED="2009-07-18 10:23:01 +1200" MODIFIED_BY="James M N Duffy" ORDER="38" O_E="0.0" SE="1.0690449676496976" STUDY_ID="STD-Bergh-1994" TOTAL_1="9" TOTAL_2="9" VAR="1.1428571428571428" WEIGHT="11.777021722062289"/>
<DICH_DATA CI_END="21.727136317813617" CI_START="0.3608390855251433" EFFECT_SIZE="2.8" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="2" LOG_CI_END="1.3370024891678427" LOG_CI_START="-0.44268642648340445" LOG_EFFECT_SIZE="0.4471580313422192" MODIFIED="2009-07-18 10:27:30 +1200" MODIFIED_BY="James M N Duffy" ORDER="61" O_E="0.0" SE="1.0453980786557544" STUDY_ID="STD-Hazout-2003-4-IU" TOTAL_1="12" TOTAL_2="6" VAR="1.092857142857143" WEIGHT="9.81418476838524"/>
<DICH_DATA CI_END="20.577596931490746" CI_START="0.1349903872170238" EFFECT_SIZE="1.6666666666666667" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" LOG_CI_END="1.3133946561246959" LOG_CI_START="-0.8696971568919833" LOG_EFFECT_SIZE="0.22184874961635637" MODIFIED="2009-07-18 10:27:35 +1200" MODIFIED_BY="James M N Duffy" ORDER="62" O_E="0.0" SE="1.2823589374447564" STUDY_ID="STD-Hazout-2003-8-IU" TOTAL_1="12" TOTAL_2="6" VAR="1.6444444444444444" WEIGHT="8.832766291546717"/>
<DICH_DATA CI_END="8.50188452641712" CI_START="0.735131132465979" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.929515202033078" LOG_CI_START="-0.13363518468900268" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2009-07-18 10:24:52 +1200" MODIFIED_BY="James M N Duffy" ORDER="153" O_E="0.0" SE="0.6244997998398398" STUDY_ID="STD-Kueuk-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.39" WEIGHT="29.442554305155724"/>
<DICH_DATA CI_END="51.868815695195885" CI_START="0.46080162516829903" EFFECT_SIZE="4.888888888888889" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.7149063319937174" LOG_CI_START="-0.33648599789999234" LOG_EFFECT_SIZE="0.6892101670468626" MODIFIED="2008-10-02 07:42:38 +1300" MODIFIED_BY="James M N Duffy" ORDER="40" O_E="0.0" SE="1.2049980091353687" STUDY_ID="STD-Owen-1991" TOTAL_1="13" TOTAL_2="12" VAR="1.452020202020202" WEIGHT="6.359591729913636"/>
<DICH_DATA CI_END="54.80326328921184" CI_START="0.07734492566419716" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7388064195482726" LOG_CI_START="-1.1115681736042693" LOG_EFFECT_SIZE="0.3136191229720017" MODIFIED="2008-10-02 07:42:49 +1300" MODIFIED_BY="James M N Duffy" ORDER="42" O_E="0.0" SE="1.6743241455995954" STUDY_ID="STD-Suikkari-1996-4-IU" TOTAL_1="10" TOTAL_2="3" VAR="2.803361344537815" WEIGHT="5.005234231876472"/>
<DICH_DATA CI_END="20.755198842579816" CI_START="1.459854471639657" EFFECT_SIZE="5.504504504504505" ESTIMABLE="YES" EVENTS_1="13" EVENTS_2="3" LOG_CI_END="1.3171268984382924" LOG_CI_START="0.1643095644735012" LOG_EFFECT_SIZE="0.7407182314558968" MODIFIED="2009-07-18 10:26:14 +1200" MODIFIED_BY="James M N Duffy" ORDER="63" O_E="0.0" SE="0.6771706085087554" STUDY_ID="STD-Tesarik-2005" TOTAL_1="50" TOTAL_2="50" VAR="0.4585600330281181" WEIGHT="19.608741167233713"/>
<DICH_DATA CI_END="30.4180684674257" CI_START="0.7086617768667252" EFFECT_SIZE="4.642857142857143" ESTIMABLE="YES" EVENTS_1="5" EVENTS_2="2" LOG_CI_END="1.4831316331038475" LOG_CI_START="-0.1495609911746122" LOG_EFFECT_SIZE="0.6667853209646176" MODIFIED="2008-10-02 07:43:14 +1300" MODIFIED_BY="James M N Duffy" ORDER="43" O_E="0.0" SE="0.9590517294600015" STUDY_ID="STD-Zhuang-1994" TOTAL_1="12" TOTAL_2="15" VAR="0.9197802197802198" WEIGHT="9.159905783826224"/>
</DICH_OUTCOME>
</COMPARISON>
<COMPARISON ID="CMP-003" MODIFIED="2009-08-11 15:41:06 +1200" MODIFIED_BY="jane clarke" NO="3">
<NAME>Growth hormone versus placebo: Poor responder as demonstrated by previous sub-optimal response following controlled ovarian stimulation</NAME>
<DICH_OUTCOME CHI2="0.594457034084126" CI_END="50.39173741041417" CI_START="0.6690557235285726" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="5.806451612903227" ESTIMABLE="YES" EVENTS_1="6" EVENTS_2="0" I2="0.0" I2_Q="0.0" ID="CMP-003.01" LOG_CI_END="1.702359332254317" LOG_CI_START="-0.17453770971624993" LOG_EFFECT_SIZE="0.7639108112690335" METHOD="MH" MODIFIED="2009-08-11 13:59:43 +1200" MODIFIED_BY="Julie A Brown" NO="1" P_CHI2="0.44070092364699187" P_Q="0.0" P_Z="0.11061402739715931" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="USER" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="15" WEIGHT="100.0" Z="1.595439327791918">
<NAME>Live birth rate per woman randomised</NAME>
<GROUP_LABEL_1>Growth Hormone</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<DICH_DATA CI_END="247.83320377698894" CI_START="0.5658461212078016" EFFECT_SIZE="11.842105263157896" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="0" LOG_CI_END="2.394159491108236" LOG_CI_START="-0.24730165679116894" LOG_EFFECT_SIZE="1.0734289171585336" ORDER="78" O_E="0.0" SE="1.5516073537196706" STUDY_ID="STD-Owen-1991" TOTAL_1="13" TOTAL_2="12" VAR="2.407485380116959" WEIGHT="38.30645161290323"/>
<DICH_DATA CI_END="54.80326328921184" CI_START="0.07734492566419716" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7388064195482726" LOG_CI_START="-1.1115681736042693" LOG_EFFECT_SIZE="0.3136191229720017" ORDER="81" O_E="0.0" SE="1.6743241455995954" STUDY_ID="STD-Suikkari-1996-4-IU" TOTAL_1="10" TOTAL_2="3" VAR="2.803361344537815" WEIGHT="61.693548387096776"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.4338665634229425" CI_END="6.4623222354380765" CI_START="1.0291918735672592" CI_STUDY="95" CI_TOTAL="95" DF="3.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.5789473684210527" ESTIMABLE="YES" EVENTS_1="19" EVENTS_2="8" I2="0.0" I2_Q="0.0" ID="CMP-003.02" LOG_CI_END="0.8103886097607773" LOG_CI_START="0.012496348390592018" LOG_EFFECT_SIZE="0.4114424790756847" METHOD="MH" MODIFIED="2009-08-11 14:10:39 +1200" MODIFIED_BY="Julie A Brown" NO="2" P_CHI2="0.9331609553503064" P_Q="0.0" P_Z="0.043242851922883005" Q="0.0" RANDOM="NO" SCALE="88.49399640781036" SORT_BY="STUDY" STUDIES="4" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="62" TOTAL_2="54" WEIGHT="100.00000000000001" Z="2.0213567162899917">
<NAME>Pregnancy rate per woman randomised</NAME>
<GROUP_LABEL_1>GH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<DICH_DATA CI_END="14.223640757660439" CI_START="0.21531055600870871" EFFECT_SIZE="1.75" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="2" LOG_CI_END="1.1530107749157927" LOG_CI_START="-0.6669346775432038" LOG_EFFECT_SIZE="0.24303804868629442" MODIFIED="2009-07-18 07:31:19 +1200" MODIFIED_BY="James M N Duffy" ORDER="82" O_E="0.0" SE="1.0690449676496976" STUDY_ID="STD-Bergh-1994" TOTAL_1="9" TOTAL_2="9" VAR="1.1428571428571428" WEIGHT="22.396416573348265"/>
<DICH_DATA CI_END="8.50188452641712" CI_START="0.735131132465979" EFFECT_SIZE="2.5" ESTIMABLE="YES" EVENTS_1="10" EVENTS_2="5" LOG_CI_END="0.929515202033078" LOG_CI_START="-0.13363518468900268" LOG_EFFECT_SIZE="0.3979400086720376" MODIFIED="2009-07-18 07:28:25 +1200" MODIFIED_BY="James M N Duffy" ORDER="104" O_E="0.0" SE="0.6244997998398398" STUDY_ID="STD-Kueuk-2008" TOTAL_1="30" TOTAL_2="30" VAR="0.39" WEIGHT="55.99104143337067"/>
<DICH_DATA CI_END="51.868815695195885" CI_START="0.46080162516829903" EFFECT_SIZE="4.888888888888889" ESTIMABLE="YES" EVENTS_1="4" EVENTS_2="1" LOG_CI_END="1.7149063319937174" LOG_CI_START="-0.33648599789999234" LOG_EFFECT_SIZE="0.6892101670468626" ORDER="83" O_E="0.0" SE="1.2049980091353687" STUDY_ID="STD-Owen-1991" TOTAL_1="13" TOTAL_2="12" VAR="1.452020202020202" WEIGHT="12.094064949608063"/>
<DICH_DATA CI_END="54.80326328921184" CI_START="0.07734492566419716" EFFECT_SIZE="2.0588235294117645" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="0" LOG_CI_END="1.7388064195482726" LOG_CI_START="-1.1115681736042693" LOG_EFFECT_SIZE="0.3136191229720017" ORDER="90" O_E="0.0" SE="1.6743241455995954" STUDY_ID="STD-Suikkari-1996-4-IU" TOTAL_1="10" TOTAL_2="3" VAR="2.803361344537815" WEIGHT="9.518477043673013"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0" CI_END="0.0" CI_START="0.0" CI_STUDY="95" CI_TOTAL="95" DF="0.0" EFFECT_MEASURE="OR" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="9" I2="0.0" I2_Q="0.0" ID="CMP-003.03" LOG_CI_END="-Infinity" LOG_CI_START="-Infinity" LOG_EFFECT_SIZE="-Infinity" METHOD="MH" MODIFIED="2009-08-11 14:10:49 +1200" MODIFIED_BY="Julie A Brown" NO="3" P_CHI2="0.0" P_Q="0.0" P_Z="0.0" Q="0.0" RANDOM="NO" SCALE="1000.0" SORT_BY="STUDY" STUDIES="1" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="9" TOTAL_2="9" WEIGHT="0.0" Z="0.0">
<NAME>Number of women with at least one oocyte retrieved per woman randomised</NAME>
<GROUP_LABEL_1>GH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<DICH_DATA CI_END="0.0" CI_START="0.0" EFFECT_SIZE="0.0" ESTIMABLE="NO" EVENTS_1="9" EVENTS_2="9" LOG_CI_END="0.0" LOG_CI_START="0.0" LOG_EFFECT_SIZE="0.0" MODIFIED="2009-07-18 07:33:21 +1200" MODIFIED_BY="James M N Duffy" ORDER="93" O_E="0.0" SE="0.0" STUDY_ID="STD-Bergh-1994" TOTAL_1="9" TOTAL_2="9" VAR="0.0" WEIGHT="0.0"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="1.4149382125643826" CI_END="10.783259879650917" CI_START="0.37616130577546425" CI_STUDY="95" CI_TOTAL="95" DF="2.0" EFFECT_MEASURE="OR" EFFECT_SIZE="2.014012193817521" ESTIMABLE="YES" EVENTS_1="17" EVENTS_2="10" I2="0.0" I2_Q="0.0" ID="CMP-003.04" LOG_CI_END="1.032750071956995" LOG_CI_START="-0.4246258806423216" LOG_EFFECT_SIZE="0.30406209565733666" METHOD="MH" MODIFIED="2009-08-11 15:41:06 +1200" MODIFIED_BY="jane clarke" NO="4" P_CHI2="0.49289013745850785" P_Q="0.0" P_Z="0.41344810596009596" Q="0.0" RANDOM="NO" SCALE="223.14980997208497" SORT_BY="STUDY" STUDIES="3" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="25" TOTAL_2="15" WEIGHT="100.0" Z="0.8178407987166786">
<NAME>Embryo transfer per woman randomised</NAME>
<GROUP_LABEL_1>GH</GROUP_LABEL_1>
<GROUP_LABEL_2>Placebo</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours Placebo</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours GH</GRAPH_LABEL_2>
<DICH_DATA CI_END="93.83451750382918" CI_START="0.11980894485244409" EFFECT_SIZE="3.3529411764705883" ESTIMABLE="YES" EVENTS_1="9" EVENTS_2="8" LOG_CI_END="1.9723626252009203" LOG_CI_START="-0.9215107566124854" LOG_EFFECT_SIZE="0.5254259342942175" MODIFIED="2009-07-18 08:41:24 +1200" MODIFIED_BY="James M N Duffy" ORDER="98" O_E="0.0" SE="1.6998755493814637" STUDY_ID="STD-Bergh-1994" TOTAL_1="9" TOTAL_2="9" VAR="2.8895768833849327" WEIGHT="21.27500267408279"/>
<DICH_DATA CI_END="10.016750351294176" CI_START="0.015973244254742544" EFFECT_SIZE="0.4" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="1" LOG_CI_END="1.0007268499339175" LOG_CI_START="-1.7966068672779927" LOG_EFFECT_SIZE="-0.3979400086720376" ORDER="99" O_E="0.0" SE="1.6431676725154984" STUDY_ID="STD-Suikkari-1996-12-IU" TOTAL_1="6" TOTAL_2="3" VAR="2.7" WEIGHT="55.620922023745855"/>
<DICH_DATA CI_END="73.38389052399133" CI_START="0.2967651022898275" EFFECT_SIZE="4.666666666666667" ESTIMABLE="YES" EVENTS_1="7" EVENTS_2="1" LOG_CI_END="1.8656007326081483" LOG_CI_START="-0.5275871706909968" LOG_EFFECT_SIZE="0.6690067809585756" ORDER="97" O_E="0.0" SE="1.4057704208690964" STUDY_ID="STD-Suikkari-1996-4-IU" TOTAL_1="10" TOTAL_2="3" VAR="1.9761904761904763" WEIGHT="23.104075302171356"/>
</DICH_OUTCOME>
<DICH_OUTCOME CHI2="0.0742210647252155" CI_END="12.585886674280285" CI_START="0.2099506390919817" CI_STUDY="95" CI_TOTAL="95" DF="1.0" EFFECT_MEASURE="OR" EFFECT_SIZE="1.6255506607929517" ESTIMABLE="YES" EVENTS_1="3" EVENTS_2="1" I2="0.0" I2_Q="0.0" ID="CMP-003.05" LOG_CI_END="1.099883816958876" LOG_CI_START="-0.6778827990270007" LOG_EFFECT_SIZE="0.2110005089659377" METHOD="MH" MODIFIED="2009-08-11 14:11:20 +1200" MODIFIED_BY="Julie A Brown" NO="5" P_CHI2="0.7852872384403584" P_Q="0.0" P_Z="0.6417520840187205" Q="0.0" RANDOM="NO" SCALE="117.67367031596203" SORT_BY="STUDY" STUDIES="2" SUBGROUPS="NO" SUBGROUP_TEST="NO" SWAP_EVENTS="NO" TAU2="0.0" TOTALS="YES" TOTAL_1="23" TOTAL_2="15" WEIGHT="100.00000000000001" Z="0.46525049415838976">
<NAME>Adverse Events</NAME>
<GROUP_LABEL_1>Treatment</GROUP_LABEL_1>
<GROUP_LABEL_2>Control</GROUP_LABEL_2>
<GRAPH_LABEL_1>Favours treatment</GRAPH_LABEL_1>
<GRAPH_LABEL_2>Favours control</GRAPH_LABEL_2>
<DICH_DATA CI_END="25.40447040006716" CI_START="0.15745260330203248" EFFECT_SIZE="2.0" ESTIMABLE="YES" EVENTS_1="2" EVENTS_2="1" LOG_CI_END="1.4049101457243374" LOG_CI_START="-0.8028501543963749" LOG_EFFECT_SIZE="0.3010299956639812" ORDER="104" O_E="0.0" SE="1.296849328880646" STUDY_ID="STD-Owen-1991" TOTAL_1="13" TOTAL_2="12" VAR="1.6818181818181817" WEIGHT="58.14977973568283"/>
<DICH_DATA CI_END="34.03196072720281" CI_START="0.035895864419677063" EFFECT_SIZE="1.105263157894737" ESTIMABLE="YES" EVENTS_1="1" EVENTS_2="0" LOG_CI_END="1.5318869713842018" LOG_CI_START="-1.444955583822021" LOG_EFFECT_SIZE="0.043465693781090345" ORDER="102" O_E="0.0" SE="1.7486120525364364" STUDY_ID="STD-Suikkari-1996-4-IU" TOTAL_1="10" TOTAL_2="3" VAR="3.057644110275689" WEIGHT="41.85022026431719"/>
</DICH_OUTCOME>
</COMPARISON>
</ANALYSES_AND_DATA>
<FIGURES MODIFIED="2009-08-11 15:41:07 +1200" MODIFIED_BY="jane clarke">
<FIGURE FILENAME="Risk of bias summary.png" FILE_TYPE="PNG" ID="FIG-01" MODIFIED="2009-08-11 15:39:01 +1200" MODIFIED_BY="jane clarke" NO="1" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_TABLE_PLOT">
<CAPTION>
<P>Methodological quality summary: review authors' judgements about each methodological quality item for each included study.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAARoAAAJwCAIAAADZVjlMAAAa4ElEQVR42u3dvW4kxRrG8ZFICBw4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</FILE>
</FIGURE>
<FIGURE FILENAME="Risk of bias graph.png" FILE_TYPE="PNG" ID="FIG-02" MODIFIED="2009-08-11 15:39:01 +1200" MODIFIED_BY="jane clarke" NO="2" SHORT_VERSION_FIGURE="YES" TYPE="QUALITY_GRAPH_PLOT">
<CAPTION>
<P>Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAeAAAADOCAMAAADR2yFVAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-03" MODIFIED="2009-08-11 14:02:45 +1200" MODIFIED_BY="Julie A Brown" NO="3" REF_ID="CMP-001.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Growth hormone versus placebo: Routine use, outcome: 1.1 Live birth rate per woman randomised.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqYAAACgCAMAAADpY16ZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-04" MODIFIED="2009-08-11 14:04:12 +1200" MODIFIED_BY="Julie A Brown" NO="4" REF_ID="CMP-001.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Growth hormone versus placebo: Routine use, outcome: 1.2 Pregnancy rate per woman randomised.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqgAAACQCAMAAADz0GmHAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-05" MODIFIED="2009-08-11 14:04:27 +1200" MODIFIED_BY="Julie A Brown" NO="5" REF_ID="CMP-001.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Growth hormone versus placebo: Routine use, outcome: 1.3 Number of women with at least one oocyte retrieved per woman randomised.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqgAAACQCAMAAADz0GmHAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-06" MODIFIED="2009-08-11 14:04:38 +1200" MODIFIED_BY="Julie A Brown" NO="6" REF_ID="CMP-001.04" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Growth hormone versus placebo: Routine use, outcome: 1.4 Embryo transfer per woman randomised.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAACQCAMAAAD3Jbm6AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA
AMAAwMD////AwMD/gICA/4CAgP/g4OBAAAAAQAAAAECAgID/gAAAAAALCwsWFhYhISEsLCw3NzdC
QkJNTU1YWFhjY2Nubm55eXmEhISPj4+ampqlpaWwsLC7u7vGxsbR0dHc3Nzn5+cAAAAAADMAAGYA
AJkAAMwAAP8AMwAAMzMAM2YAM5kAM8wAM/8AZgAAZjMAZmYAZpkAZswAZv8AmQAAmTMAmWYAmZkA
mcwAmf8AzAAAzDMAzGYAzJkAzMwAzP8A/wAA/zMA/2YA/5kA/8wA//8zAAAzADMzAGYzAJkzAMwz
AP8zMwAzMzMzM2YzM5kzM8wzM/8zZgAzZjMzZmYzZpkzZswzZv8zmQAzmTMzmWYzmZkzmcwzmf8z
zAAzzDMzzGYzzJkzzMwzzP8z/wAz/zMz/2Yz/5kz/8wz//9mAABmADNmAGZmAJlmAMxmAP9mMwBm
MzNmM2ZmM5lmM8xmM/9mZgBmZjNmZmZmZplmZsxmZv9mmQBmmTNmmWZmmZlmmcxmmf9mzABmzDNm
zGZmzJlmzMxmzP9m/wBm/zNm/2Zm/5lm/8xm//+ZAACZADOZAGaZAJmZAMyZAP+ZMwCZMzOZM2aZ
M5mZM8yZM/+ZZgCZZjOZZmaZZpmZZsyZZv+ZmQCZmTOZmWaZmZmZmcyZmf+ZzACZzDOZzGaZzJmZ
zMyZzP+Z/wCZ/zOZ/2aZ/5mZ/8yZ///MAADMADPMAGbMAJnMAMzMAP/MMwDMMzPMM2bMM5nMM8zM
M//MZgDMZjPMZmbMZpnMZszMZv/MmQDMmTPMmWbMmZnMmczMmf/MzADMzDPMzGbMzJnMzMzMzP/M
/wDM/zPM/2bM/5nM/8zM////AAD/ADP/AGb/AJn/AMz/AP//MwD/MzP/M2b/M5n/M8z/M///ZgD/
ZjP/Zmb/Zpn/Zsz/Zv//mQD/mTP/mWb/mZn/mcz/mf//zAD/zDP/zGb/zJn/zMz/zP///wD//zP/
/2b//5n//8z///80TKWtAAANnElEQVR42u1dO48lRxWuuXNna40WZDM77I7AWieQMEQbOYEEEZUQ
EpGJiIj9Gwj5DYjQMY8jEuQEJwQ4Yi1LtgxCWiOb3RHGGLylmVlzb3d1dT27q7ur+3bf+33anX5U
1anT1V+fOlV9btcRZwCwBKzQBACoCgCgKnB4WM9fRbH5T5u/xMo/vYVoMcF02sVVmXVbKlT66mOa
XsWZablaAFOJVJsMAuURM9lVWfoWlKHD1nK9AKayzA+qMhX2hlV2m01hvMqrErUV0hu3+uKM2Bos
wWgq9Wap5QH6qqK0BMpiaMMhrKMJ2SCsjVN9qSzVT9NOuoZZaLleBLm0+csBoxnJOr0jkDA2Qneg
pWmajdOyey0XYVVJu0VD+C4qj9/x/IWY04VqbYh2M96brZaH4wAQRZqViGg+SjLT5os5MnVXWs6e
qqP2Lco4CMHYtB1tcVXGIEVtxLyYOS8tj+YfA5BpXrU2qaJ+BMgQP+UMQF2RqlhvzOmIahwTSJ+0
7eeh5RHCVYBlAC9WAVAVAEBVAFQFAFAVAEBV4BBgxgCoybEi7sA8G58iq0q052yDG/lopVFrfhFW
YhypZUIVmEBuDj2F6wUf6VLMmSYu2zHYfqbcOhSCCjnCTho2Mz93/UyqltoJEh2uriyR5aGhZhZ7
uc0LFxNLTalIdL56am3ssq2pIoOfNBpmoN86cLN01KH5jqh6McHctxHE6pw6q3qBQcbzVJ2lVu7X
ZZUcEX8BUgdKxt+RjCC1eqBF4BJZVZl3c1rMQP1KqLZQFLdiWn62kN5562f5qkJpQJZyth5kxXo7
UUlVzKfqSMkLXRRJr/StGFJSRAiWLM+XWdrC/HNLVedrIfrChRG82bMzJqsl7cTdh4LtRL+VbeP9
WqghdsYrQW3dbsPd21yhcGsip3WauyghppLa4gZQSidq31F1RG4sSKjVVRRJdlLMXL+13/l3uriu
JRKdPfcSKSHQLPiMjyN1iFdqOU7+Q24HMlnKmoPYYvTbZVyxfP3WoT6tK1nH8eK9epqfiYTxZTap
VNgWUhYm/VEVxlg7mkNEZNL4gYqz1m/leKqerWiaZzBKCMu+iIZWaGU+BbQZFiI5jtRQQyTdKzOU
22t07RoLUQlUe8L2RwTZfVs+msxUv5Xtlgn1Qxmqnh3b5jiuilGC6u6BbC39DHFfNViN0ifiLZsq
i6mkhtvEbq1Af0OpT4bbbNU5cq5CBG/LgEd6zvqlxat2qkhEY6Bn+euLjN1nn+DvFE9f0G4vah76
rZOI2qn9aepQ9bmgz4WDqZmtKgAAwGLx48C5Yw/5HABYVaAvAty5Tsk0eAYAAOYMUBUAVQEAVAUO
EMa8quT1Xw/OaZW3dJrtTW6kSe+sg3UFnaWGrt88wQMNKetBhltwWyAgxaxV11imcVvD4oRk/ECo
yiWPMtVpBKlbb/Pf3mRnapL0zjpYV9BZqgwn1yck98XyeEEWlmLUKq37IB0N1WMgD8WqOrZEt5i2
EbURCDXKSE80z5jLJKFMl8r7lY73TbxR8VCqqlFG2l9Ow1LRcrzBr1sLBUCdqcqlNqyGTVAPuHl+
+f0MH7t00FYHfIJm94O7NZbWgk9kJloolfZCNdtbV8uqcslb7kvQ/6o34zRZYpfer3KZJLWT8G0/
JJtpKCuPM0zpaGrAYdnvXr/FAYjfAYe3sjwnF+sljaR6Ew2Z4Zvyrql8ogtYOlX9R9rx5RZoVHma
VJnFFx6jfQ7ovfgqvXOUrLH3XyJT5UhMHVSt7JAkD4epIauqOnqvbwk5ACpjYXDHmVhVYnmz8LRc
7T5NUGrsypzrN6ov96Mz1HZBS5iXaj0mtr6y+wUvGYhXnQNa5nbzdkDZEJoBuB7kYvZ3AIDJuDob
IfsxrAJGm4nIMm7ioCoAzIBPcACAhQBUBUBVAABVAVAVAEBVAABVAVAVAEBVAABVAVAVAEBVAABV
AVAVAEBVYLk4Obp/9vpXvvzS6fk3Tp5llIsfrAB94f5g5dk74ubq5snpZXm43d49Xq9urd67DaoC
86Dqyb2bq+dXT6M5763/++Zrf89HVbWGr6+IscB9yprvu1gQxNCLppEqjJQ6g16u213xy2jcKreo
j8kT4a5rI+pmN+9ILZO6LoSTh6oPfvHTO1dffTcp/90fvHVy3N/CmkusETMWxxWhG1cvBlesGEf2
raPEJf/GYGq1knLOhTSbpIpghmrPpwzpJfaqPKKWSgERwqpU1GKYuehitRY3Y1Pz9NmD8z+eviTf
+9Enjz9+91SdbN4+feN/f33/6MXXz+6/fdKjxnXElgjTiFbt5JpZFlzznaanKo0plSL2tpsjp1uN
mG0Qw5XaycLu3bprkxOPvnN+9d0/3L3c+qLq/2WH7ce/vGQXpy+sj2/99tu3h1G1XKyRqsUrhaBA
ezR3NmL/F1gb8jyKUA/fnEzWQr0kMmrTAZ9/6d7zn/zqm+xv7I3N0eXA/+yCna1Ojo//eZVhsiq+
wOhoa9IP6a3Hk+oJb12Z3W+YWobqtWPOSiDZLknTdCo+Pvg6++KDnAKfs+c/6+OrJtx/xV3ldm0c
J0EzWaJyWqa2mdxxGoYo2ZSMg4vHHz353ad3Hr3y4vnXCv+z//+z+y+/8ujOZ59c/vzDRKPa/Ltt
/xbRLgZNS2PqdBru5HZcPdy4AuyLd3746a1r5X8WfXra9vTo/vF6/aeLzZmHvWcAUtp7sjXpF8hU
8+pj3vomT1MjecnWkZckdrjw8u2HH37v8t+f3fnLg9v3S73UzH98e3b+8tvfevqffz396PFFjxqt
VwCi8ucZ6am6wmenqvlrl7/cGr6TnlfdwahK1I9LxlsnzCELhXhszasKQwHhOZVCT4i6k7EiKKI+
4VVXibEan6Zfw954BXB97+b65kks4+n2ndXx0HdWHd5WJVuXg1xhfaQuoctjvzuqlnj2wvnVTfHO
Sr9bffXPR5+/+do/rnJU1+XFamKzCTC1z9xVBqbumKrKwrJ719fPr9jq+78//Q2/yFcdYgCAvFQd
DQgCBBYCUBUAVQEAVAVAVQAAVQFgEIwYALVAh7+2X9saM+OuQSP18uRZq1FLHB/Uenp7Q1U++cJH
qZRS65Xm1E6awoGlOgBSSrUSXrHnnGZ1wiZPMGdO7HI1TGCmVtW2Y9w1ZeZBtV/k4SMYvbEBpu7Z
sCq8rqhBST7J7R/1GZDgwHKtauw+yoYbvNBlab0lj4GFUrXo1oNWkwcM8FjGb0yjCkdgTxwAz3xu
baf2VyfqRsdkKizqsq1q1ZlvB0xG/2j28U5/X+Qca6xezn2OUwHHvOpSqcqdv7z6Z3SWPJRlvBvO
R+qqORyAPXMAAABUBQBQFQBVAWBXwM8A9xTD5/haJQzP0EkJWFVggQ6ANP7ae6mPQOCVQapE6afK
nmoA8FXbwEMEHFIcADTWMRPHWRFDJdXrfb3LZPluVScYMfrbI6nzF+wzXsMqicwpW4moQg7MkP8q
BdH6Pby88SXI8XVoo6ofsVrvlpx1EnS4KpfqTSyPSfTKVpsqn18rovXzdHGLHFZFqCrTrtuMm/OV
4dqkWmY1IIwHRfDxXqYCe+MAVL1zykBIJlr6EFe7dxwYWgHrFiPK0/qXTvbPDoNNygD7CqzaDVvU
xEUMq2NHg2H20ighQ9KllwLDOq2r2i6Bj6+DKWId7rSNiFXtUpa7KobVjvQ0jiR3PWozuxp7lfxV
Q389A6D3nQyIK+07IrHnT/S8Ck8u2Zi3WU6nDy1YmSNffuj1YrXlWhMHfj6pgZxM1bMmzqcUJOOp
JRvzNsuR2jQl3GArc+zLD51fAcgNsjAV2B2Fc+RNsalZVVrn94F4N0kg9nydWN5bDs+vEsJVgKXP
AAAAqAoAoCqwv4h/X9UenUnWcUhnj+qkNXtqjfqC4S1WsjPJpiJiPH3C84gHOx/Bq/g1Y0Y87SbW
JXMp0SlzTN0j3jJrINNmjZupKn3KuOku7exvDppTfUqWDAZv+WUwd7bHDoD6Vmr9mVXzE6qyevMZ
+tqq/53VSoiZWMmVcabyXpMeA8oAS3IAHPNkhpg6oaus4WurNvGsyFczvnV7insdOLM+3hIz2OEy
8W4F1N1XqrbYJ27TwP7aaiIreIh9vJmc7jczeUIZYM+pKrt6xDK46x/L3rRyPoQKIoKqJhHSB4Hc
7vCj9pMnEJ6Hmcx7lDl4iO0f6pw9ssxvbPXfjrXoJbZLeelrCq8TZ5vaHEFj6aBG3vgTCrL55ynN
MxAc3X8TqHv2HstRdywhqN+i16sQ/YrYKbXR1ONWSJV5ZOxz6cZVGydqwbyeSpBFrJaM2UxZThvU
cqIfRFdZvDLgLRNClMZPqH19UJ8JFdlujAPnqGctBUtJDHUAuOMAMOdLqiz8Gz5u7QY+ymp/hJWb
Y7Amcxn7RSBvsLD4FWGjGXNM2mY3aOTUSf3PPhE0it1qoaFUXQI6Tj4dtFEtvcKSFiTIZxhZG6F3
KcQpylOLLiH2naodjeVBm1aDgvE8IsAlu4jIWktRQj8VYp+pCvRxABqZFnYAuvXWPWoZPKwC9nPa
yumZRYvJFN5GZKmlGFGJg/BVgc5ugKhH3KojNk7ZXbNdZLupc9hHvWuJCWgDPgUMLARwAABQFQBA
VQBUBQBQFQBAVQBUBQBQFQBAVQBUBYDd4f8r0zdyZ//P3gAAAABJRU5ErkJggg==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-07" MODIFIED="2009-08-11 14:04:48 +1200" MODIFIED_BY="Julie A Brown" NO="7" REF_ID="CMP-001.05" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Growth hormone versus placebo: Routine use, outcome: 1.5 Mean number of ampoules of gonadotrophin used per woman.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAsgAAACQCAMAAAAiN233AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-08" MODIFIED="2009-08-11 14:06:12 +1200" MODIFIED_BY="Julie A Brown" NO="8" REF_ID="CMP-001.06" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 1 Growth hormone versus placebo: Routine use, outcome: 1.6 Adverse Events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAACgCAMAAADzX74XAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-09" MODIFIED="2009-08-11 14:10:05 +1200" MODIFIED_BY="Julie A Brown" NO="9" REF_ID="CMP-002.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Growth hormone versus placebo: Poor responder as defined by the study, outcome: 2.1 Live birth rate per woman randomised.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAssAAADACAMAAADFjt4DAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-10" MODIFIED="2009-08-11 15:40:11 +1200" MODIFIED_BY="jane clarke" NO="10" REF_ID="CMP-002.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 2 Growth hormone versus placebo: Poor responder as defined by the study, outcome: 2.2 Pregnancy rate per woman randomised.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqYAAAEACAMAAABWCETDAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-11" MODIFIED="2009-08-11 14:10:32 +1200" MODIFIED_BY="Julie A Brown" NO="11" REF_ID="CMP-003.01" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Growth hormone versus placebo: Poor responder as demonstrated by previous sub-optimal response following controlled ovarian stimulation, outcome: 3.1 Live birth rate per woman randomised.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAssAAACgCAMAAADNetFZAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-12" MODIFIED="2009-08-11 14:10:41 +1200" MODIFIED_BY="Julie A Brown" NO="12" REF_ID="CMP-003.02" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Growth hormone versus placebo: Poor responder as demonstrated by previous sub-optimal response following controlled ovarian stimulation, outcome: 3.2 Pregnancy rate per woman randomised.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqYAAADACAMAAADhl1HDAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-13" MODIFIED="2009-08-11 14:11:06 +1200" MODIFIED_BY="Julie A Brown" NO="13" REF_ID="CMP-003.03" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Growth hormone versus placebo: Poor responder as demonstrated by previous sub-optimal response following controlled ovarian stimulation, outcome: 3.3 Number of women with at least one oocyte retrieved per woman randomised.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqYAAACQCAMAAADtGVk0AAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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==
</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-14" MODIFIED="2009-08-11 15:41:07 +1200" MODIFIED_BY="jane clarke" NO="14" REF_ID="CMP-003.04" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Growth hormone versus placebo: Poor responder as demonstrated by previous sub-optimal response following controlled ovarian stimulation, outcome: 3.4 Embryo transfer per woman randomised.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqgAAACwCAMAAAD0fGyxAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
<FIGURE FILENAME="Forest plot.png" FILE_TYPE="PNG" ID="FIG-15" MODIFIED="2009-08-11 14:11:24 +1200" MODIFIED_BY="Julie A Brown" NO="15" REF_ID="CMP-003.05" SETTINGS="SHOW_EFFECT_SIZE_COLUMN:YES;SHOW_WEIGHT_COLUMN:YES;SHOW_RAW_DATA_COLUMNS:YES;" SHORT_VERSION_FIGURE="YES" TYPE="FOREST_PLOT">
<CAPTION>
<P>Forest plot of comparison: 3 Growth hormone versus placebo: Poor responder as demonstrated by previous sub-optimal response following controlled ovarian stimulation, outcome: 3.5 Adverse Events.</P>
</CAPTION>
<FILE>iVBORw0KGgoAAAANSUhEUgAAAqoAAACgCAMAAADzX74XAAADAFBMVEUAAADAAAAAwAAAAMDg4ADA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</FILE>
</FIGURE>
</FIGURES>
<FEEDBACK/>
<APPENDICES MODIFIED="2009-08-10 07:32:32 +1200" MODIFIED_BY="James M N Duffy">
<APPENDIX ID="APP-01" MODIFIED="2009-08-10 07:32:32 +1200" MODIFIED_BY="James M N Duffy" NO="1">
<TITLE MODIFIED="2009-07-20 15:24:48 +1200" MODIFIED_BY="Julie A Brown">MDSG search terms</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-10 07:32:32 +1200" MODIFIED_BY="James M N Duffy">
<P>Search string for KH291 MDSG database 28.06.09</P>
<P>Keywords CONTAINS  "growth hormone" or "growth hormone derivative" or "human growth hormone" or  "growth hormone releasing factor" or "grf" or Title CONTAINS "growth hormone" or "growth hormone derivative" or "human growth hormone" or  "growth hormone releasing factor" or "grf"</P>
<P> </P>
<P>AND</P>
<P>Keywords CONTAINS "IVF" or "in vitro fertilization" or "IVF" or "ICSI" or "intracytoplasmic sperm injection" or "Embryo" or "in-vitro fertilization" or Title CONTAINS "IVF" or "in vitro fertilization" or "IVF" or "ICSI" or"intracytoplasmic sperm injection" or "Embryo" or "in-vitro fertilization"</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-02" MODIFIED="2009-08-10 07:32:32 +1200" MODIFIED_BY="James M N Duffy" NO="2">
<TITLE MODIFIED="2009-07-13 07:48:35 +1200" MODIFIED_BY="James M N Duffy">MEDLINE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-10 07:32:32 +1200" MODIFIED_BY="James M N Duffy">
<P>Database: Ovid MEDLINE(R) &lt;1950 to June Week 3 2009&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 growth hormone/ or human growth hormone/ (47027)<BR/>2 somatotrop$.tw. (5778)<BR/>3 (somatrop$ or norditropin).tw. (184)<BR/>4 (growth adj5 hormone$).tw. (48524)<BR/>5 or/1-4 (64412)<BR/>6 fertilization in vitro/ or sperm injections, intracytoplasmic/ (22271)<BR/>7 IVF.tw. (11335)<BR/>8 (in Vitro adj5 fertili$).tw. (14828)<BR/>9 icsi.tw. (3589)<BR/>10 (intracytoplas$ adj5 sperm).tw. (3510)<BR/>11 exp Ovulation Induction/ (8201)<BR/>12 ((ovar$ or ovulat$) adj5 (induct$ or stimulat$)).tw. (9654)<BR/>13 or/6-12 (37952)<BR/>14 exp growth hormone-releasing hormone/ or exp sermorelin/ (4583)<BR/>15 (growth hormone adj5 releasing factor).tw. (1341)<BR/>16 grf.tw. (1855)<BR/>17 or/14-16 (5630)<BR/>18 or/5,17 (65464)<BR/>19 18 and 13 (460)<BR/>20 randomized controlled trial.pt. (273632)<BR/>21 controlled clinical trial.pt. (79523)<BR/>22 randomized.ab. (183258)<BR/>23 placebo.tw. (116263)<BR/>24 clinical trials as topic.sh. (144111)<BR/>25 randomly.ab. (132970)<BR/>26 trial.ti. (79814)<BR/>27 (crossover or cross-over or cross over).tw. (43128)<BR/>28 or/20-27 (648343)<BR/>29 (animals not (humans and animals)).sh. (3296848)<BR/>30 28 not 29 (600179)<BR/>31 30 and 19 (71)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-03" MODIFIED="2009-08-10 07:32:32 +1200" MODIFIED_BY="James M N Duffy" NO="3">
<TITLE MODIFIED="2009-07-17 06:35:53 +1200" MODIFIED_BY="James M N Duffy">EMBASE search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-08-10 07:32:32 +1200" MODIFIED_BY="James M N Duffy">
<P>Database: EMBASE &lt;1980 to 2009 Week 26&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 growth hormone/ or growth hormone derivative/ or human growth hormone/ (37552)<BR/>2 somatotrop$.tw. (3622)<BR/>3 (somatrop$ or norditropin).tw. (653)<BR/>4 (growth adj5 hormone$).tw. (39350)<BR/>5 or/1-4 (52850)<BR/>6 fertilization in vitro/ or intracytoplasmic sperm injection/ (23933)<BR/>7 IVF.tw. (11213)<BR/>8 (in Vitro adj5 fertili$).tw. (12921)<BR/>9 icsi.tw. (3793)<BR/>10 (intracytoplas$ adj5 sperm).tw. (3461)<BR/>11 ovary hyperstimulation/ or ovulation induction/ (9384)<BR/>12 ((ovar$ or ovulat$) adj5 (induct$ or stimulat$)).tw. (8632)<BR/>13 or/6-12 (35212)<BR/>14 5 and 13 (468)<BR/>15 exp growth hormone releasing factor/ or exp "growth hormone releasing factor[1-29]"/ (4982)<BR/>16 (growth hormone adj5 releasing factor).tw. (1135)<BR/>17 grf.tw. (1494)<BR/>18 or/15-17 (5770)<BR/>19 or/5,18 (53914)<BR/>20 19 and 13 (479)<BR/>21 Clinical Trial/ (545660)<BR/>22 Randomized Controlled Trial/ (170304)<BR/>23 exp randomization/ (26900)<BR/>24 Single Blind Procedure/ (8278)<BR/>25 Double Blind Procedure/ (72902)<BR/>26 Crossover Procedure/ (21458)<BR/>27 Placebo/ (128084)<BR/>28 Randomi?ed controlled trial$.tw. (33843)<BR/>29 randomised controlled trials.tw. (2814)<BR/>30 random allocation.tw. (641)<BR/>31 randomly allocated.tw. (10334)<BR/>32 allocated randomly.tw. (1359)<BR/>33 (allocated adj2 random).tw. (562)<BR/>34 Single blind$.tw. (7573)<BR/>35 Double blind$.tw. (85680)<BR/>36 ((treble or triple) adj blind$).tw. (140)<BR/>37 placebo$.tw. (111457)<BR/>38 prospective study/ (83224)<BR/>39 or/21-38 (716803)<BR/>40 case study/ (6169)<BR/>41 case report.tw. (120958)<BR/>42 abstract report/ or letter/ (502683)<BR/>43 or/40-42 (627435)<BR/>44 39 not 43 (691822)<BR/>45 44 and 20 (92)</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-04" MODIFIED="2009-07-31 05:27:25 +1200" MODIFIED_BY="James M N Duffy" NO="4">
<TITLE MODIFIED="2009-07-20 15:22:55 +1200" MODIFIED_BY="Julie A Brown">CENTRAL search Strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-31 05:27:25 +1200" MODIFIED_BY="James M N Duffy">
<P>Database: EBM Reviews - Cochrane Central Register of Controlled Trials &lt;2nd Quarter 2009&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 growth hormone/ or human growth hormone/ (2525)<BR/>2 somatotrop$.tw. (157)<BR/>3 (somatrop$ or norditropin).tw. (43)<BR/>4 (growth adj5 hormone$).tw. (3238)<BR/>5 or/1-4 (3704)<BR/>6 fertilization in vitro/ or sperm injections, intracytoplasmic/ (1223)<BR/>7 ivf.tw. (1610)<BR/>8 (in Vitro adj5 fertili$).tw. (1203)<BR/>9 icsi.tw. (547)<BR/>10 (intracytoplas$ adj5 sperm).tw. (339)<BR/>11 exp Ovulation Induction/ (717)<BR/>12 ((ovar$ or ovulat$) adj5 (induct$ or stimulat$)).tw. (1076)<BR/>13 or/6-12 (3192)<BR/>14 exp growth hormone-releasing hormone/ or exp sermorelin/ (300)<BR/>15 (growth hormone adj5 releasing factor).tw. (43)<BR/>16 grf.tw. (71)<BR/>17 or/14-16 (344)<BR/>18 or/5,17 (3736)<BR/>19 18 and 13 (64)<BR/>20 limit 19 to yr="2007 -Current" (2)<BR/>21 from 20 keep 1-2 (2)<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
<APPENDIX ID="APP-05" MODIFIED="2009-07-31 05:27:26 +1200" MODIFIED_BY="James M N Duffy" NO="5">
<TITLE MODIFIED="2009-07-20 15:23:39 +1200" MODIFIED_BY="Julie A Brown">psycINFO search strategy</TITLE>
<APPENDIX_BODY MODIFIED="2009-07-31 05:27:26 +1200" MODIFIED_BY="James M N Duffy">
<P>Database: PsycINFO &lt;1806 to June Week 1 2009&gt;<BR/>Search Strategy:<BR/>--------------------------------------------------------------------------------<BR/>1 growth hormone/ or human growth hormone/ (969)<BR/>2 somatotrop$.tw. (151)<BR/>3 (somatrop$ or norditropin).tw. (5)<BR/>4 (growth adj5 hormone$).tw. (1777)<BR/>5 or/1-4 (1922)<BR/>6 fertilization in vitro/ or sperm injections, intracytoplasmic/ (0)<BR/>7 ivf.tw. (239)<BR/>8 (in Vitro adj5 fertili$).tw. (353)<BR/>9 icsi.tw. (24)<BR/>10 (intracytoplas$ adj5 sperm).tw. (16)<BR/>11 exp Ovulation Induction/ (0)<BR/>12 ((ovar$ or ovulat$) adj5 (induct$ or stimulat$)).tw. (177)<BR/>13 or/6-12 (581)<BR/>14 exp growth hormone-releasing hormone/ or exp sermorelin/ (0)<BR/>15 (growth hormone adj5 releasing factor).tw. (41)<BR/>16 grf.tw. (45)<BR/>17 or/14-16 (63)<BR/>18 or/5,17 (1943)<BR/>19 18 and 13 (3)<BR/>20 from 19 keep 1-3 (3)<BR/>
<BR/>
</P>
</APPENDIX_BODY>
</APPENDIX>
</APPENDICES>
<EXTENSIONS/>
</COCHRANE_REVIEW>